Poly-MVA
How POLY-MVA (LAMCs)
Can Help You:
Improve Overall Health
Be Anti-Aging
Increase Energy & Vitality
Increase Endurance
Prevent and Heal from Cancer
Used in Metabolic and Degenerative Conditions by targeting the Mitochondria
James W. Forsythe, M.D., H.M.D Board Certified Oncologist
POLY-MVA is composed of alpha lipoic acid (a powerful water- and fat-soluble antioxidant) bonded with the vitamin thiamin B1 and the mineral palladium. It exists as a formulation, with other unique vitamins, minerals and amino acids, called Poly-MVA.
POLY-MVA has salutary effects in healthy people, promoting energy production and offering potent antioxidant protection at the cellular level. When used accordingly, POLY-MVA also appears to have the unique capacity to negatively affect neoplastic cells (since they favor anaerobic metabolism, which does not require oxygen) while supporting healthy tissues. In fact, unlike most modern chemotherapeutic compounds, POLY-MVA enhances and supports the health of the body while the body is dealing with these abnormal cells.
Research on POLY-MVA is continuing to build at present. Efforts are being made so that other LAMC compounds can undergo the U.S. Federal Drug Administration (FDA) approval process to be available to pharmaceutical medicine. Multiple studies have demonstrated LAMC’s ability to not only act as an antioxidant to protect normal tissue, chromosomes and DNA from damage, while providing enhanced cellular energy by potentiating aerobic metabolism at the mitochondria. These scientific findings have led to Investigational New Drug (IND) studies to alleviate fatigue associated with numerous clinical conditions. In contrast, in cancer cells, studies have demonstrated LAMC’s ability to potentiate chemo and radiotherapy, while reducing their harmful side effects. This book will share and summarize this updated information
Our purpose here is to introduce you to this unique complex and to its remarkable potential. This book will share the currently available information so that you can make an educated decision as to why POLY-MVA might be useful to you. Waiting for the results of
FDA approval will take many years - years that many cancers, degenerative disease and chronically ill patients just do not have.
We will primarily discuss the mitochondrial mechanism with its positive impact and cancer supporting benefits of POLY-MVA, because most of the clinical research that has been done has had to do with cancer patients. Cancer patients are faced with frightening choices, and they need to know there are safe, effective and complimentary/integrative therapies and how one unique option like POLY-MVA may help. The complex’s effects for metabolic diseases like cancer are quite amazing, providing results and outcomes unlike any other compound or nutrient combination. We will also address the many other ways in which POLY-MVA supports health and aids in our bodies process ability to prevent disease and stay healthy
As research and case reports accumulate, there is increasing evidence that using POLYMVA in varying doses for health maintenance may not only help to prevent cancer, but it also has protective and metabolic support for a wide range of healthy physiological functioning. Periodically check in with the listings in the Resources section to stay up to date on new information.
On December 23, 1971, President Richard Nixon signed legislation that officially declared “WAR” on cancer, in some ways we have come to understand that war on anything only causes more hurt and suffering and has allowed an ineffective approach and paradigm to exist longer than it should. Cancer as a health problem was already growing at a pandemic rate and at the time most people believed that if enough money and scientific effort were thrown at it, cancer could be defeated. With the advent of new therapies and treatments, we had defeated many diseases that had once killed thousands of people each year; cancer, it would seem, was just the next foe in the line to be decimated by the brilliant minds and advanced technology of the medical research community.
From 1972 to 2022 more than 28.8 million Americans have died from cancerapproximately 1,600 people each day. That is approximately 48,000 each month, and 560,000 per year. The number of cancer diagnoses continues to rise steadily, as it has throughout the past half century. Cancer has surpassed heart disease to become the leading cause of death in this country, not to mention the deaths from the side effects of many of the cancer treatments
Despite enormous government resources, non-profits and taxpayer funding – easily upwards of $150 billion since the declaration on cancer began back in the 1970’s - cancer is likely to become the leading cause of death for all age categories in the United States, having pushed out cardiovascular disease in 2012. It has already surpassed heart disease in some age groups and the overall impact to society is truly staggering
Cancer is a far more formidable foe than the Nixon administration or anyone else realized. It can occur in any one of nearly 100 different forms. Each form can require a different approach to treatment. The cancer cell’s ability to adapt and change to multiple environments,
treatments and protocols has been shown to be very difficult. Even when one therapy works, cancer has a habit of returning in a new and more virulent form. Cancer survivors have to remain vigilant, watching for the return of the disease - particularly within the first five years after remission has been achieved (five years being the magical threshold at which the individual is thought to be cured), although some cancers like breast cancer, renal cell cancer, melanomas and thyroid cancers can lay dormant for years before recurring. Modern medicine has no answer for this, they continue to ignore what current research is showing that in one way they are only treating the symptom, they don’t understand or target the cause of the disease. They only treat it after the fact like so many other conditions. Like heart disease inflammation in our bodies in any way over a period of time to any one of our systems in many ways is the root cause of many diseases and cellular breakdown.
THE NEWS ISN'T ALL BAD!
Success stories have been coming in from many places and all around the globe. New ways of thinking about cancer and approaching is cause and treatment has emerged. The human spirit to collaborate, share knowledge and experience has changed the face of this once dreaded disease. Hope and inspiration have emerged to create a new paradigm of integrative oncology that we can change our thinking and our approach to bring positive opportunities to a formidable foe we call cancer. The first and best approach is through early detection, education and awareness. Oncologists (cancer doctors) can now identify and treat some cancers early enough to greatly improve chances of long-term survival, (many treatments really haven’t changed, many are simply living longer because of an earlier diagnosis, not necessarily improved approaches). Although children under the age of fourteen have a higher risk of dying from cancer than any
other cause at this point in history, childhood cancer treatments have released many young people from what would once have been a certain death sentence.
The American Cancer Society estimates that in 2022, greater than 18.0 million Americans called themselves cancer survivors. Still, no one would question that cancer is still a formidable adversary, and it will more than likely continue to affect more and more people.
The progress made against cancer with mainstream medical and scientific advances is primarily due to the use of early detection, screenings and educational awareness. Improved surgical techniques, low dose radiation and chemotherapeutic drugs or other targeted agents have somewhat improved certain cases and types of cancer. However, when all cancers are combined rates have hardly changed for the better and more people are getting cancer in this world than ever before. According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide, of which 5.6 million occured in economically developed countries and 7.1 million in economically developing countries. The corresponding estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in economically developed countries and 4.8 million in economically developing countries. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer deaths. (Society, 2008) These treatments have been a focus of cancer research since this “FALSE UNDERSTANDING” on cancer began and improvements on the delivery of these treatments have somewhat reduced the damage they inflict on other bodies systems. This overwhelming emphasis on the treatment of cancer with mainstream medical practices has, however, diverted attention from simple solutions: prevention first and foremost, and then when the next option is necessary an integrative or
complimentary medical approach is by far more effective for the patients and upholds the practioners primary responsibility of “DUE NO HARM”.
PREVENTION IS KEY
Many experts agree and research continues to support that many, if not most, forms of cancer are preventable. Some people are more vulnerable to cancer than others because of biological predispositions or genetic factors, but there is much that can be done to prevent cancer within those parameters. The drastic increases in cancer rates over the past century are not due to some unknown reasons or things out of our control. They are directly related to the lifestyle that has become more and more standard in the modern western world which includes: poor diet, nutrient deficient food, engineered or chemically altered food and livestock, unhealthy or chronic stress, industrial pollutants, smoking, excessive exposure to ultraviolet and other types of radiation, toxic chemicals used to make plastics and other modern materials, pesticides, toxic metals, and a host of other substances, even prior chemotherapy agents, that simply did not exist 100 years ago but have become ubiquitous today. Since the 1950’s there now exists well over 70,000 new chemicals in our environment that in many ways our bodies have to cope with and we have no idea how these chemical combinations impact our health over the long run, although common sense tells us that the more chemicals that are added the more complicated the condition and added stress to our bodies is created. Unremitting stress in our lifestyles and lack of physical exercise all combine together to create an environment for inflammation and have been shown to alter the body's chemistry in ways that predispose us and can accelerate us to degenerative disease and the normal variations of abnormal/cancer cells that are bodies develop
since the day we were created.
Cancer prevention entails doing what one can do to avoid chemicals, toxins and poisons known to contribute or to cause cancer, and reinforcing the body's natural defenses against disease with the best possible combination of diet, exercise, stress management and supplements - always keeping in mind that carcinogenesis and cancer promotion are always a combination of nature (genetic and biological factors) and nurture (environmental factors).
In many cases, cancer prevention just is not an option. The disease has already taken hold in millions of people. Many individuals may have genetic or biological predispositions to cancer that have little to do with their lifestyle choices or at least ones that we are not aware of at this point. We need treatments that work while not causing some of the side-effects that are worse than the disease, we need treatments that do not take such an enormous toll on the bodytreatments that work with the body's natural healing energies and processes without harming the immune and lymphatic systems (two of the body's most important natural defenses against cancer). And, we need more of these approaches right now!
CHANGING THE WAY WE LOOK AT CANCER THERAPY
As you will learn in the next chapter, cancer and other degenerative disease are a group of diseases characterized by uncontrolled growth, metabolic disfunction, cellular breakdown on various levels and/or a disruption in the way cells utilize energy and function that causes them in some cases to multiply without control or differentiation or improperly. In the words of Frank Antonawich, Ph.D., research scientist and neurobiologist, cancer is "an invasive event that leads to massive physiological disruption."
Most current cancer therapies focus on the use of highly toxic therapies to try and kill off as many cancerous (rapidly dividing) cells as possible. The collateral damage from this approach is considerable. Adverse toxicities of chemotherapy, radiation and surgery are notoriously dangerous and can cause severe disabilities, other illnesses, and even death. Because so many cancer patients who undergo these treatments end up dying, it is impossible to know how many of their deaths were at least partly due to these toxic treatment regimens. Sometimes, frankly speaking, the treatments can be worse than the disease itself.
Current therapies typically require that we cut, poison, burn, medicate, and otherwise damage our bodies both physically and mentally in order to rid ourselves of the cancer and other diseases. The key to better outcomes on all fronts in regard to cancer is to approach it more intelligently, with a greater understanding and with the best, safest tools available. The best treatments for cancer would “DO NO HARM” and selectively target cancerous cells or repair the degenerative pathways while simultaneously protecting and strengthening healthy cells.
POLY-MVA may support the body to achieve just that.
Before we get into the details of how POLY-MVA works, let's establish a basic understanding of what cancer is and how it develops.
2. What is Cancer?
The cells that make up each of our organs are specialized in their structure and function. Heart cells are designed to contract and release again and again to pump blood. Liver cells are made to filter and neutralize toxins. Lung cells, uterine cells, testicular cells, prostate cells, bone cells and breast cells are other illustrations of cellular differentiation (specialization).
When the DNA (genetic material) of a healthy, differentiated cell is changed/altered or in some way affected to disrupt the normal pathways in a way that it transforms or is transformed into a dysfunctional/cancerous cell, the expression of the genes of that cell is changed and is often times directly related to its metabolic and/or energy pathways. This process is known as cancer initiation. The descendants of that cell lose their specialized structure and function, and no longer perform their duties in the body. These cells do not mature into normal cells and are called "undifferentiated". As cancer progresses, cells become less specialized (poorly differentiated) - an adaption known as "anaplasia" that enables the cells to divide more quickly.
Genes carry master instructions for proper function to our trillions of cells. One of the duties of genetic material is to modulate or adjust the growth and death of cells. Proto-oncogenes are genes that, when mutated or otherwise altered, become transformed into oncogenes, genes that promote cancer formation and growth. These proto-oncogenes are strongly affected by environmental influences, such as diet, ultraviolet light, chemicals, toxins, radiation and smoking. Once these oncogenes have formed they are no longer respond to normal physiological cues, and the stage is set for the abnormal cellular development and cancer.
The genetic programming of cancer cells enables them to live as long as they have access
to nutrients and a place to grow. Healthy cells are programmed to die after a certain span of time - a form of programmed cell death known as "apoptosis". This makes room for the new cells to take the place of old ones. In cancerous cells, apoptosis is shut off and so they grow and multiply unabated and autonomously, crowding out healthy cells and in many cases moving around the body creating cancer in other locations(known as metastasis).
CANCER INITIATION - HOW CANCER STARTS
Science's understanding of cancer initiation is constantly improving. Two major categories of initiators have been discovered: toxic chemicals and free radicals.
TOXIC CHEMICALS
Certain chemicals have been found to directly alter cellular DNA in ways that transform healthy cells into cancerous ones. Such chemicals may be synthetic - for example, petroleum products, chemotherapy agents, dioxins, phthalates, and the synthetic estrogens that have been used for hormone replacement therapy. Or they may be natural, such as the molds, bacteria, viruses, or certain metals found in nature such as nickel, arsenic, uranium, cadmium, and certain forms of chromium. Even hormones naturally made within the body, such as estrogens, can be carcinogenic if not properly balanced with other hormones. So much of our health is all about balance across our entire lifestyle.
FREE RADICALS/OXIDATIVE STRESS/REACTIVE OXYGEN SPECIES(ROS)
Molecules are the basic building blocks of cells, and atoms are the building blocks of molecules. Atoms are made up of a core of protons (which have a positive charge) and neutrons (which have a neutral charge). Electrons (which have a negative charge) orbit around this core. The number of protons, neutrons and electrons in the atom tell us what element that atom is. Atoms are arranged along the periodic table of elements according to these numbers.
A molecule is a group of atoms bonded together in a specific configuration; for example, a water molecule is made up of two hydrogen atoms and one oxygen atom, and a glucose molecule is made up of six carbon atoms, twelve hydrogen atoms and six oxygen atoms. The bonds between the atoms in a molecule are created by the sharing of a pair of electrons. Electrons, like people, prefer to travel in pairs. When a molecule is split - as it is during the process of metabolism - the electron pairing that held the two now-separated atoms together is also split, and this creates a free radical - a compound that contains an unpaired electron.
Free radicals are highly reactive(ROS). Their tendency is to find another electron to form a pair. In the process of acquiring another electron, free radicals react with many kinds of molecules in the body. They can directly oxidize (steal an electron) DNA, RNA, cell membranes and other organelles causing damage to both cells' genetic information. This kind of damage can transform healthy cells into cancerous ones by damaging them and altering their DNA.
Free radicals will steal electrons from proteins and fats to become stable, and are likely to grab electrons from intact cell membranes. Once they have stolen an electron to balance themselves out, however, the source of that electron is often transformed into a free radical itself. This is how free-radical chain reactions begin, and these kinds of chain reactions would cause significant damage were it not for the existence of antioxidants. (The body's electron transport
chain, which will be described later, also plays a role in controlling oxidative stress, or freeradical damage).
Antioxidants are nutrients (like vitamins A, C and E, beta-carotene, flavonoid, isoflavones, selenium, zinc and coenzyme Q10, or substances produced in the body (including alpha-lipoic acid and glutathione) that exchange electrons with free radicals. Once it has acquired or released the unpaired electron, the free radical in question is safely neutralized.
Cancer initiation does not mean that a diagnosis of cancer is inevitable. A healthy/normal immune system knows how to recognize and eliminate cancerous cells. Every person's body contains some cells that have undergone abnormal/cancerous changes, the adult human body is made up of about 30-50 trillion cells About 2 trillion cells are produced by an adult human body every day. This is about 4 million new cells per second! All cells wear out or get damaged, they must be replaced. These new cells are formed when older cells divide. Normal and healthy cell division , or cell reproduction occurs in humans and other organisms at different times and at different rates in their life. A number of factors influence how, when and how rapidly normal and abnormal(cancer) cells multiply. In many cases of prostate cancer, for example, cancer cells multiply so slowly that no treatment may be necessary other than "watchful waiting". Different types of cancer multiply at different rates, and a slower-growing tumor may morph into a faster-growing one in response to environmental or internal factors.
Multiplying cancer cells invade tissues, organs and obstruct lymphatic channels and blood vessels along with damaging effects. They interfere with the normal process of many of normal systems, they can block circulation and generally disrupt the normal processes of our body ultimately to the point that it can no longer function and then we expire.
Compared with normal cells, cancer cells are adapted to a less efficient type of
metabolism. Two types of metabolism - the process by which sugars, fats and proteins are "burned" as fuel in the cells' metabolic machinery and turned into energy - exist in the cells of most life forms that require oxygen. There is aerobic (requiring oxygen) metabolism, an intricate biochemical process that leads to the net formation of 38 units of energy and some water. There is also anaerobic metabolism (without oxygen), which nets only two units of energy per unit of fuel. Cancer cells rely on anaerobic metabolism, also known as "glycolysis", regardless of if oxygen is present
TUMOR FORMATION
If the cancer initiation is not stopped, groups of damaged, undifferentiated cells grow together. Once enough cells have been produced from divisions of the initial cancerous cell, a tumor is detectable. Tumors can be benign or malignant. They grow at variable rates. Benign tumors may divide to form enormous masses (for example, uterine fibroids), but they do not invade surrounding normal tissues. They are rarely life-threatening. Malignant tumors (neoplasms) are made up of individual cells, cords of cells, and nests of cells that invade tissues and spread into organs, blood and the lymph system. These ever-enlarging groups of cells are no longer under the influence of the normal cell controls. Some cancers take many years to grow large enough to cause physical symptoms; a breast tumor that is detected in a 50-year-old woman may have begun to form a decade earlier.
Once a tumor grows large enough to develop its own blood vessels - a process known as "angiogenesis" - it may sometimes "pinch off" small groups of tumor cells which then float through the lymph system or bloodstream to lodge and grow in other areas of the body. Another
characteristic of malignant cells is that they lose cell-to-cell contact. As they become less specialized, production of cell adhesion agents decreases, allowing cells to break off from the primary neoplasm. This process is called "metastasis" and is a signpost of advanced cancer that will ultimately be more difficult to treat. When this happens, the cancer may go to distant organs and become what is known as advanced stage or a Stage IV cancer. This almost always means it is tantamount to being described as advanced stage and typically incurable.
STANDARD THERAPIES FOR CANCER
Once a cancer is discovered, the usual approach of mainstream oncologists involves one or more of these strategies:
1. Surgically removing the tumor by needle biopsy, incisional biopsy, or excisional biopsy.
2. Giving chemotherapeutic drugs that may or may not be tested to target any cancerous cells that remain, or the choice of chemotherapy agents being dictated by the most current literature and clinical studies, indicating the most effective single or combination drugs available to the oncologist for that particular tumor, stage and type. Many times therapies are used “off label” (In the United States, the regulations of the Food and Drug Administration (FDA) permit physicians to prescribe approved medications for other than their intended indications)
3. Giving targeted radiation therapy in the area that was affected by cancer in hopes of catching any cancer cells which have escaped the scalpel or the
drugs. Radiation therapy can include radiating the entire area of the cancer, or giving precise radiation therapy called "CyberKnife", or "tomotherapy" to directly hone in on the cancer itself. Radiation therapy can also be applied in terms of radioactive needles containing isotopes, which emit localized radiation within a set diameter of the needle that is coated with the radioisotope. It often can be stated that radiation therapy is given by the radiation therapist following surgery and chemotherapy without any evidence that remaining malignant tissue is present. It is done more-or-less as an insurance effort to kill any residual living cancer cells. Many cancer patients also receive high doses of steroid drugs, such as prednisone, for the control of edema (fluid buildup) and inflammation. While controlling the inflammatory reaction, this can lead to devastating side-effects as well.
Most of the effort behind the “war” on cancer has focused on these three treatment modalities, in addition to instruments for early detection, such as mammograms, Pap smears, and prostate-specific antigen (PSA) testing. Cancer therapies have come a very long way in one regard since their earliest days of mustard gas use as the first chemotherapy. Never before have cancer treatments been able to target cancerous growths and sometimes spare healthy cells.
Still, chemotherapeutic drugs are mostly highly toxic. They are designed to target rapidly dividing cells, and so often the cells of the body that divide the quickest - including those at the roots of hair and teeth, in bone marrow, and in the lining of the gastrointestinal tract(mouth throught the large intestine) – are usually affected and attacked. Nausea, vomiting, diarrhea, sore mouth, loss of taste, loss of immune function, hair loss and tooth loss are frequent side-effects.
In addition to extreme fatigue and anemia resulting from the harsh chemical destruction of the cells, the patient's immunity suffers, and the cancer patient can now be vulnerable to many other life-threatening infections. It is not uncommon for cancer patients receiving chemotherapy to require either or both red blood cell stimulating factors such as epogen or Procrit in order to treat chemotherapy-related anemias, and also to concurrently require white blood cell stimulating factors such as neupogen or Neulasta. A point to be made and noted is that the moment another drug of any form is used in the patient, any studies done on any of the drugs is no longer valid unless the studies included that drug in its original protocol of testing.
Surgeries are often necessary to remove tumors, but cancer cells can be left behind where they multiply and form a new tumor. Radiation therapy may also be used to try and "clean up" any remaining cancerous cells following surgery, or it may be used when tumors cannot be dealt with surgically. Unfortunately, radiation is a potent carcinogen itself and can cause painful skin burns in most patients.
THE DEVELOPMENT OF SAFER CANCER TREATMENTS
Those who research and provide mainstream cancer treatments are trying to work within the U.S. Food and Drug Administration (FDA) guidelines to develop better, safer treatments which attempt to extend life and eliminate cancer from the body. This field has been making improvements in the delivery of targeted lower dose chemotherapy and radiation that attempts to limit the destruction of healthy cells while destroying cancer cells. Meanwhile, the field of complimentary or integrative and non-conventional cancer protocols continues to expand, especially from the understanding of Metabolics/Metabolism/Mitochondria. Growing numbers of cancer patients are turning to these options and treatments to avoid the cut, burn and poison
approach of mainstream oncology, to ameliorate the negative side-effects of chemotherapy and radiation, or to enhance a mainstream approach. Complimentary/Alternative Medicine (CAM) cancer treatments can be seen as clear alternatives to allopathic approaches, and they can be viewed as an adjuvant/integrative approach to be used along with more traditional methods. Alternative cancer medicine seeks safer and less toxic ways to treat cancer. It makes use of a holistic view of this disease and figures out what tools the body needs to reverse and remove the growth of cancer while minimizing collateral damage. Our bodies know and have the mechanisms to deal with cancer and its effects, many times we just need the resources and the time to give it that opportunity and the trouble with late-stage cancers is we are usually short on both.
Recent ground-breaking research into a specific class of compounds – lipoic acid mineral compounds - is revealing that they may become the centerpiece of safe, effective and nontoxic cancer therapies. These accounts, case studies, research programs, outcome studies and individual stories of people who have used these compounds are nothing less than amazing. You will hear many of these from real people a little later in the book. Now, read on to learn about POLY-MVA and other compounds, and about their role in protecting healthy cells, supporting healthy metabolic function that can lead to recovery, repair, healing and prevention of cancer.
The lipoic acid mineral family of compounds was discovered by Dr. Merrill Garnett. Dr.
Garnett was initially and formally trained as a dentist. In dental school he saw many cases of various oral cancers, and his interest in cancer research was piqued. He earned graduate degrees in biochemistry and electrochemistry, which evolved into over 40 years of scientific bench work. He is head of the Garnett McKeen Laboratories in Bohemia, New York. For most of his career as an electrochemist - spanning the past 40 years - Dr. Garnett has researched molecular and cellular biology in order to better understand how abnormal cells more specifically cancer works and to find effective, safe approaches to targeting cellular support and keeping healthy cells health while targeting the abnormal ones that could one day be used in cancer treatments.
Dr. Garnett was interested in cellular metabolism and so at the time built upon the groundwork and the research of German scientist Otto Warburg, a Nobel Prize winner. Dr. Warburg believed and showed that cancerous tumors are oxygen deficient (anaerobic). Current research has demonstrated that cancer cells are not anaerobic but hypoxic (low oxygen).
However, they do rely primarily upon anaerobic metabolism for the majority of their energy production. Anaerobic metabolism produces less energy per unit of fuel, which means decreased energy efficiency in tumor cells. Although these cells are less efficient, this shift is believed to be a form of cellular energy conservation, because less energy is produced.
Dr. Garnett looked at this research and asked, "If changes in gene expression alter cellular metabolism in this way, could this be used to somehow target cancerous cells for destruction while leaving healthy cells (those that still utilize primarily aerobic metabolism) alone? Could this decreased energy production be a result of natural selection, where mutant cells that are better able to conserve energy are the ones that survive and multiply?"
Dr. Garnett's research focused on ways to identify the enzyme and energy changes that cause the shift from aerobic to anaerobic metabolism, and finding ways to prevent it. Dr. Garnett
and other investigators sought a way to utilize the anaerobic energy default mechanism used by cancer cells to bring about their demise.
THE PRODUCT OF DR. GARNETT'S SEARCH
In his book First Pulse, Dr. Garnett describes how he searched for "the signaling mechanism by which cells migrate together to form tissues and organs. The cancer cell state is a single cell type of behavior; cancer cells do not form tissues and organs. The organizing communications are missing." In other words, Dr. Garnett sought to discover the metabolic or chemical signal that tells cells when to form tissues and organs; in so doing, he hoped to discover why cancer cells lack this signal, and how to correct or interrupt this process. By understanding the course of events that triggers the formation and differentiation of normal cells, Dr. Garnett hoped to discover ways to restore these normal events to cancerous cells. "How are these communications interrupted?", Dr. Garnett asked.
In the course of his research, Dr. Garnett saw that cancer cells were not necessarily malicious entities but simply immature/ undifferentiated cells. He sought to discover a catalyst or an enzyme (a substance that catalyzes the activity of biochemical machinery) which would trigger the electron oxygen pathway in order to provide the conditions required by DNA to process developmental changes. He hypothesized that just such an enzyme was missing in cancer cells. By replacing it, he hoped to trigger both the maturation of normal cells and the destruction of these immature, undifferentiated cells.
Dr. Garnett screened thousands of organometallic compounds (minerals bound to organic compounds), and he finally discovered the safe and effective cellular supportive and apoptotic
agent LAMC. The principles that led to this finding in the early 1990's continue to drive Dr. Garnett's principal laboratory interests: ultra-low frequency electrical currents are at the heart of all physiological processes, and that by regulating charge transfer we can develop several new methods of medicinal management.
After more than twenty years of research and laboratory testing with more than 20,000 compounds, Dr. Garnett developed a synthetic enzyme that could facilitate a sort of "selective electrocution" of tumor cells by shuttling electrons into the mitochondria and DNA. This enzyme appeared to be able to target cells that relied upon anaerobic metabolism - cancerous cells - while leaving normal cells intact He sought one that could predictably be damaging to cancerous cells and yet supportive of healthy ones
Dr. Garnett's rationale for choosing to test specific compounds had to do with complex scientific theories regarding the electrochemical charges he found in DNA and in cells. In fact, his research gave rise to an entirely new field of study called "electrogenetics", which studies the energy reactions through which the living state interacts with its hereditary material, DNA. In other words, Dr. Garnett discovered that electrochemical energy is an important "language" used by DNA to communicate with the cell in which it resides, and that this energy is also used for intercellular communication.
Dr. Garnett's electrogenetic research is backed by testing, research and highly sensitive electronic studies. Other scientists have studied this electrical genetic pulse, but no other scientist has so deeply delved into its implications, especially in the field of cancer at that time. Using sensitive instruments, Dr. Garnett found and was able to measure, beneath the pulse of the heart and all living tissue, a cellular pulse - a vibration that is clearly see in the living from the dead, and also in the healthy cells from abnormal cells. Dr. Garnett believes that the difference
between life, death, normal and abnormal in the cell and the body is the transfer or movement of electrical energy through the cells and their DNA, which contains our genes.
Cellular metabolism is, in the end, a simple electrochemical process. When glucose enters a cell it is broken down into a substance called acetyl-coA, which is then channeled into a process known as the "Krebs cycle" or citric acid cycle. This cycle does not occur in anaerobic metabolism, which is a more primitive form of energy production. The Krebs cycle uses acetylcoA to produce a high-energy substance known as nicotinamide adenine dinucleotide (NADH), which is then oxidized - it donates an electron in a part of the metabolic process called the "electron transport chain".
The energy is released along the electron transport chain in the form of voltage jumps. That electrochemical energy is captured in reactions that preserve it in the form of adenosine triphosphate (ATP), the energy currency of the body. Any energy needs on the part of the body are filled by the splitting of ATP into adenosine diphosphate (ADP) and a free phosphate molecule.
Dr. Garnett new that electron transfer held the key to understanding the genetic signaling that would transform, control and all cells into healthy or abnormal ones. He sought to create a sort of "liquid transistor" consisting of a mineral and an organic compound (hence, a metalloorganic compound). This liquid transistor would act as an enzyme and affect the electron transfer to DNA. Because of the unique biochemical and electrical properties of minerals when bound to organic compounds, he believed that this would be the key. He was right, but it took decades for him to find the right combination. Thousands of biological molecules and several dozen minerals fell into this category of good candidates for such a compound.
Eventually, after over thirty years of research, Dr. Garnett struck pay dirt. A specific combination of the mineral palladium and the organic molecule alpha-lipoic acid proved to rapidly and efficiently transfer electron charge to DNA. When palladium is sequestered in alpha-lipoic acid, it is benign - useful, in fact - to healthy cells and not beneficial to abnormal cells. The transfer of electron energy to DNA by lipoic acid/mineral complexes has been measured and reported in three U.S. patents. To create POLY-MVA, Dr. Garnett added the B vitamin thiamine to create a molecule with a unique structure.
Experiments with cell cultures and mice with cancerous tumors indicated that the lipoic acid/mineral complex was damaging to cancer cells but had no adverse effects on healthy cells. One day, in the early 1990's, the laboratory mice treated with this compound stopped dying from their once fatal form of cancer, and analysis showed that the compound was selectively eliminating cancerous cells and safe for normal cells.
This is how POLY-MVA (LAMC) were created. Dr. Garnett took out several patents on this class of compounds. One form is currently in the preclinical preparation for the pharmaceutical-approval process.
THANKS TO THE SANCHEZ FAMILY...
The story of POLY-MVA would not be complete without mention of the tireless commitment of the Sanchez Family that was started by Al Sanchez, Sr., Ed.S., Ph.D. They lost their lovely wife and mother of 4 children to colon cancer in 1972, when she was only 35 years old. At the time, Al Sanchez Sr. was working in education, but the course of his life and his children had shifted dramatically after her death. Al Sr. vowed to spend much of his time in
cancer health care searching, supporting and pioneering options/opportunities for cancer patients for safe and effective treatments for cancer, especially when he realizd that outside the U.S.A. there were other treatments being tried and used. After his initial 12 years in health care, he began to bring more of his family to support this cause and has ultimately led to 2 of his remaining children, Linda and Albert to participate, support and carry on the mission of helping others, most specifically those with cancer. They have sought out substances, approaches and protocols that had scientific support as safe, healthy, integrative and cancer specific. Using his considerable people skills to network with those who research and create safer and effective cancer remedies, Al Sr.set the tone for how LAMC has helped so many people in so many ways over the years. As long as the evidence and the prime directive of “Do No Harm” was observed and honored the family conintues to work with doctors and their advanced cancer patients to try and see what can help and works best, the outcomes and long-term survival are the true measure of success in degerenative disease
The Sanchez families diligent searching paid off when Al Sr. came across Dr. Garnett and POLY-MVA. After reviewing the research and earlier success of the product, Dr. Sanchez purchased POLY-MVA for use with cancer patients. To his delight and astonishment, success stories began flooding in, some of which are included in Chapter 7 of this book.
Dr. Sanchez's approach is diametrically opposed to that of mainstream medical science. Most conventional physicians are unlikely to recommend a compound to their patients if it has not undergone rigorous, extensive clinical testing that proves its safety and efficacy and brings it FDA approval. On the other hand, if one can prove that something is safe, effective and nontoxic, and there is convincing evidence in its favor with a solid scientific basis, it is worth
trying, especially for people who are fighting for their lives and dying of cancer. POLY-MVA and other POLY-MVA fall into this category of integrative and supportive therapies in degenerative disease and especially cancer
It is true that clinical studies - the kind needed for FDA approval of a drug - were needed. The groundwork has now been laid. This is where my own research in a clinical outcome-based study, which was begun in 2002 after much discussion with Dr. Albert Sanchez, Sr., to allow an integrative study using a version of LAMC known as Poly-MVA in Stage IV adult cancer patients in an effort to achieve longevity results, improved quality of life and survival statistics on as many patients as possible that could be accrued over a five-year period. With the support of both The Foundation for the Advancement in Cancer Research and AMARC Enterprises, I would receive from these organizations the access to the product to use on Stage IV patients who did not wish to take conventional chemotherapy but rather would take the supplement PolyMVA initially and has been improved upon over the years which now includes another therapy known as the Forsythe Immune Therapy (FIT) program. These other therapies included: dietary counselling, appropriate supplements, other intravenous (IV) therapies such as high-dose vitamin C, hydrogen peroxide, our Forsythe Immune Therapy (FIT) stimulating IV, and the amino acid L-glutathione. This treatment was designed to go on for a minimum three-week period with intravenous Poly-MVA given at least three times a week for three weeks. The patient was then discharged to home on oral Poly-MVA at a dose of 8 teaspoons per day, or 40 mL of Poly-MVA in divided doses. The results from this study, from 2002 through 2005, where I had achieved a total of 225 patients, was significant, and when followed out to five years a 35% survival rate was obtained. This survival rate compared favorably to a dismal 2.1% survival rate recorded in the conventional oncology literature in the Journal of Oncology in 2004.
This study was interrupted by an FDA investigation of my practice, which involved the use of human growth hormone as an anti-aging measure for adults who were deficient. It also encompassed the study with Poly-MVA. In fact, the FDA subpoenaed all of my records from the 225-patient study in late 2005 and audited these records, and they found nothing wrong with the structure of my study nor the outcomes that I presented. My adverse incidents were extremely low (less than 1%) and the survival rate (noted to be 35% at the end of five years) was dramatically better, some seventeen times better, than the conventional literature boasted of. Since 2005, when this study was abruptly curtailed by the FDA, and after my victory in court with the FDA, I continue to use Poly-MVA along with my FIT program. When it was completed I have treated over a thousand patients with this program.
In the final study, using chemosensitivity testing followed by insulin-potentiated therapy, using tested cancer cells for targeted drugs and supplements along with Poly-MVA, I have achieved a success rate at 30 months (at the time of this writing) of 72% in over 450 patients.
Some would argue that we must not recommend any substance that has not undergone this stringent and enormously costly process, especially if we do not exactly understand how that substance does what it is purported to do. The truth is, however, that off label use of drugs is a norm for the medical industry and not just in cancer treamtents. For example, aspirin was and is used for many things long before anyone knew how it worked and in some cases we still don’t know how its mechanism can be used for so many various condtions. Throughout history, herbal and natural medicines have been used successfully without any scientific analysis of their direct effects on human physiology, there is evidence just not the amount the AMA or the pharmecutical industry says is needed as they are the only ones capable of spending the 10 to
100 of millions of dollars for testing and research.
Most clinical testing attempts to isolate the effects of a single substance on a particular disease. One common criticism of alternative cancer remedies is that they have not been tested alone - that is, without dietary changes or the addition of other supplements and/or drugs. However, it is hardly fair to expect people who are battling cancer to try only one intervention at a time. Disease is a multifactorial process, and so must be the treatment of disease - especially a disease as complex and dangerous as cancer or other degenerative conditions. Eventually, POLY-MVA will probably be studied as a sole remedy for cancer, but for now it makes sense for cancer patients to use any and all dietary changes, nutritional supplements, and medical methods at their disposal to improve their chances of feeling better, enjoying life, and finding their way to a cure.
The Sanchez Family established a nonprofit organization, The Foundation for Advancement in Cancer Research, with the intention of supporting research and getting the word out about successful integrative cancer therapies, including POLY-MVA. Slowly, the word is spreading. If you do an Internet search for POLY-MVA/PolyMVA, you will find dozens of articles, scientific information, more inspiring stories of cancer survival, and further information about Dr. Merrill Garnett's research and discovery.
4. Understanding POLY-MVA
WHAT IS LIPOIC ACID MINERAL COMPLEX?
Lipoic Acid Mineral Complex is a patented compound (LAMC). Promising evidence indicates that its ingredients can target and eliminate cancerous cells while supporting and
protecting healthy cells and helping the body in its various states of metabolic disfunction.
There is no free lipoic acid or palladium in Lipoic Acid Mineral Complex; it is irreversibly bound. Dr. Garnett created LAMC in this way to make a mineral polymer that was soluble in both fat and water. It is prepared so that it does not break down and liberate the mineral, which is not useful to the body by itself.
Joined in this fashion, lipoic acid, thiamin and palladium create a unique substance with extraordinary properties. In normal cells, this lipoic acid/mineral (LAMC) complex quenches free radicals and transfers that electrical charge from the fatty acids that make up cell membranes into the mitochondria (the cellular organelle responsible for energy production). In an abnormal cell that is metabolic challenged or inefficeint, this same compound can bring about increased or rectified metabolism and in certain situations apoptosis by upregulating or increasing the metabolic cascasde- and the abnormal cells self-destruction.
According to Dr. Frank Antonawich formerly from the State University of New York (SUNY) Stony Brook Health Sciences Center, who researches lipoic acid mineral complexes, this selective killing of cancer cells by LAMC is possible because malignant cells have adapted to this hypoxic (low oxygen) metabolic environment. The extra energy passed along to the mitochondria by LAMC causes destructive oxidative changes to the cancerous cell, releasing mitochondrial proteins and activating enzymes that trigger the apoptotic cascade that cause the cell to turn off or self-destruct.
While POLY-MVA's most significant impact has been in the cancer arena, its lipoic acid/thiamin design, increased/improved mitochondrial activity combined with its safety record and research history has allowed its many rejuvenating and healing effects on cell function to
become an ideal cellular nutrient for the support of optimal health, disease prevention and quality of life across many fronts. LAMC acts as an efficient aerobic catalyst; according to Dr. Antonawich, this leads to improved oxygen utilization and energy at the cellular level in healthy cells, which utilize aerobic metabolism. This effect is likely responsible for all the other benefits that are seen with this complex. See Chapter 8 for more on the use of POLY-MVA for support of optimal health.
POLY-MVA in its complete proprietary formulation contains alpha-lipoic acid, the mineral palladium, vitamins B1, B2 and B12, the amino acids formyl-methionine and Nacetylcysteine, and trace amounts of the mineral’s molybdenum, rhodium, and ruthenium. Each ingredient has its own unique characteristics and healing properties:
Palladium:
Palladium is a unique and rare mineral that has special electrochemical properties. In POLY-MVA, the mineral is sequestered in an organic molecule called lipoic acid mineral complex and provides the unique electrochemical, electron-transferring aspect that makes the compound so revolutionary.
Palladium is a precious mineral and quite expensive. It was used because of the results of Dr. Garnett's electrochemistry studies, where he found that DNA (and other biological cellular entities) have specific electrical frequencies. This characteristic facilitates electron flow or energy exchange, the key to what seems to trigger many cellular functions and that also initatiates the turning of our genes on and off during various times in a cell's life cycle, as well as drive aerobic metabolism, our primary source of proper cellular function and healing. Palladium was the only mineral that Dr. Garnett could appropriately combine with lipoic acid.
Alpha-Lipoic Acid (ALA):
Alpha-lipoic acid (ALA) is one of the most powerful antioxidants and detoxifiers known to man. It is soluble in both fat and water, and it readily crosses membranes throughout the body, particularly when bound to the mineral. It can pass through the protective blood-brain barrier - a characteristic that makes this nutrient ideal for moving the other components of POLY-MVA into brain cells to help heal brain cancer.
The importance of ALA in biological systems has been known since the 1950's. It is made within the body and is a necessary part of cellular metabolism. It has powerful antioxidant capacity, but it only acts as an antioxidant when supplemental amounts are available to the cells. In other words, ALA made by the body has important work to do in the energy factories of the cells, and none of it can be spared for antioxidant work unless ALA is brought in from outside the body, only tiny amounts of ALA can be found in most foods.
When enough ALA is available, it helps to directly deactivate free radicals. It also donates electrons to other antioxidants that have "spent" themselves doing the same kind of work. Alpha-lipoic acid regenerates vitamin E, vitamin C and glutathione. Glutathione is an antioxidant that is made in the body. It is a powerful cellular detoxifier, especially in the liver.
People with cancer, autoimmune disease, Covid, AIDS, mitochondrial damage, Fatigue and other diseases have been found to have low levels of glutathione. ALA is the only antioxidant that has been proven to raise glutathione levels within the cells and the two make a powerful team for our cells in multiple ways
ALA also inhibits glycation, the process by which sugars bind to proteins within the cells. When you watch a chicken browning in the oven, you are observing glycation in action. Age spots of the skin are another visible manifestation of glycation. This process is believed to be an
important cause of premature aging and age-related disease. Glycated proteins produce free radicals at a rate fifty times that of non-glycated proteins.
ALA is also an effective chelator of heavy metals. It helps to move excessive amounts of metals such as mercury, iron and copper safely out of the body. These are metals that catalyze (enhance) the production of free radicals when allowed to accumulate in excess.
Several recent studies indicate that ALA is extremely helpful for the treatment of diabetic complications (such as nerve damage in the extremities and the eyes) and may aid in the prevention of Parkinson's disease dementia and Alzheimer's disease. ALA may even be involved in nerve regeneration.
HOW POLY-MVAES WORK
The lipoic-acid mineral complexes are potent "redox polymers". Why is this significant? A redox molecule not only has the ability to accept charge (e.g., free radical scavenger), but also donate charge. In addition, data demonstrates that polymers like LAMC have greater antioxidant potential than monomolecular structures like vitamins. Most do not realize that vitamins, when serving as antioxidants to absorb electrons, must do something with those electrons. Frequently they donate them to another location like another vitamin or molecule, acting as a pro-oxidant.
Dr. Garnett's electrochemistry papers demonstrate that palladium/lipoic acid has far better antioxidant potential than any vitamin, it can simply do more work and transfer more electrons that creates more energy. POLY-MVA was tested by Brunswick Labs in Wareham, Massachusetts, for an ORAC analysis, which measures the ability of a substance to absorb free radicals in comparison to vitamin E. The results were pretty stunning, as expressed in vitamin E equivalents per gram:
Vitamin A = 1.6
Vitamin C = 1.12
Vitamin E = 1.0
Melatonin = 2.04
Lipoic acid = 1.4
POLY-MVA = 5.65
The mechanisms for the anticancer effects of POLY-MVA involve Electrogenetics understanding and the metabolic dysfunction of cancer cells and mitochondrial pathways. This phenomenon was summarized in an article by Shari Lieberman, Ph.D., C.N.S., F.A.C.N., and James W. Forsythe, M.D., H.M.D., "POLY-MVA For Treating Prostate Cancer: A Report on Three Cases". Lieberman and Forsythe report on Dr. Antonawich's HIF-1 research, which attributes POLY-MVA's anticancer effects to the way in which LAMC shunts electron energy from itself to DNA. This excess energy cannot be accepted/used by cancer cells. Within both healthy and cancerous cells, this electron energy does not go directly to the DNA but travels via the mitochondria (the powerhouse of a cell). Since malignant cells function in a hypoxic environment, free radicals generated around the mitochondrial membranes of malignant cells trigger a chain reaction involving cytochrome C and caspase enzymes. This chain reaction ends up turning off the malignant cell, apoptosis. Healthy cells, on the other hand, are richly oxygenated and get a beneficial energy boost from this infusion of electrons across the electron transport chain and complex I-IV.
This electron transfer takes advantage of the changes malignant cells undergo to physiologically adapt to a hypoxic (low energy) environment. Dr. Antonawich's group has recently been examining this phenomenon in laboratory studies. They have found that when oxygen is low, a transcription factor called Hypoxia Inducible Factor (HIF) is increased within cells. HIF is designed to help cells adapt to low oxygen levels, and has been found to be over-
expressed in several human cancers. HIF is increased in cells as they transform from noncancerous to cancerous, and its activation up-regulates:
. vascular endothelial growth factor (VEGF), the substance that is responsible for angiogenesis;
. erythropoietin (EPO), which increases the specialization of blood cells;
. glucose transporter 1 (GLUT 1), which facilitates anaerobic respiration;
. glycolytic enzymes, which are needed for anaerobic respiration;
. pyruvate kinase M2, an isoform of the gateway between glycolysis and aerobic metabolism (M2 favors cells staying in glycolysis), and
. carbonic anhydrase 9, which is responsible for converting carbon dioxide to carbonic acid for transport out of the cell - in the end, this change disrupts pH within the cell.
Overall, the effect of hypoxia is to stimulate HIF-1 activity, which in turn enables tumor cells to react to stress and continue to survive. Hypoxia is related to poor response to treatment in many types of cancer. (Bos R, et.al., "Expression of hypoxia-inducible factor-1 and cell cycle proteins in invasive breast cancer are estrogen receptor-related," Breast Cancer Research 2004;6:R450-R459). One important avenue of cancer drug research is the search for compounds that inhibit up-regulation of the alpha subunit of HIF-1, which is the subunit most closely linked with carcinogenesis and cancer growth.
Enter LAMC, which decreases HIF-1 levels. LAMC does this by mimicking the electron transport chain in aerobic metabolism, and by acting as a potent antioxidant. The results: less angiogenesis, less glycolysis, and less pH dysfunction, which increases cancerous cells'
vulnerability to apoptosis (programmed cell death).
POLY-MVA is a very promising approach the targets the metabolic disfunction of cancer. It is presently being used as an adjunct protocol/treatment for cancer by numerous physicians and other healthcare practitioners around the world. Its use is becoming increasingly widespread as doctors and patients see firsthand how the product of Dr. Garnett's decades of work can save lives and positively affect people's health when used as part of a comprehensive integrative/nutritional program for degenerative disease and cancer therapy.
5. Energy Medicine: Bridging East and West
Similarly as in the ancient times - where there was a strong dialogue between Asclepios, god of medicine, and Hygeia, goddess of health - today a new dialogue, a new language is being developed to begin to understand the concept of bioenergy/energetics as part of the holistic concept of treating the whole body, mind and spirit.
While great strides have been made in Western medicine in the treatment of certain types of illnesses with drugs and surgeries, the prevention and treatment of chronic disorders with Western medicines lags far behind. The standard biochemical model of disease is limited to pathologic degeneration and "magic-bullet" drug and surgical therapies - an approach that does not work for the treatment of disease syndromes and chronic disease, especially cancer.
Standard, conventional allopathic approaches ignore the complete systems of our body and the mind/body connection and the existence of energy fields. It is in these energetic fields that disturbances are first manifested.
Manning and Vanrenen noted in their book Bioenergetic Medicine East and West: "On the surface the mechanical, biochemical model of Western medicine is mathematical, neat and tidy, but the dynamic, chaotic nature of life and of man tends to undermine this semblance of order. Modern science has striven to make medicine into a hard science like chemistry and to avoid the unquantifiables: emotions, spirit and subjective sensations. The monumental effort drive to make medicine into a consistent, hard science solely based on biochemical data, tends to disregard the traditional art of healing based on homeostasis and bioenergy" (C. Manning, L. Vanrenen, 1988, p. 24).
The essential distinction between the biochemical model of Western medicine and Eastern medicine is the concept of energy and energy flow - the recognition of the unseen, subatomic world in dynamic action. As Dr. Larry Dossey explained in Space, Time and Medicine, "In the first place, as the physicist Wheeler has observed, 'the world is at the bottom of a quantum world and quantum system'" (L. Dossey, p. 146). This means that we will ultimately give due regard to the subatomic world. In an article in Foundation of Physics, physicist David Bohm noted, "we see that the inseparable quantum interconnectedness of the whole universe is the fundamental reality, and that the relatively behaving parts are merely particular and contingent within the whole." (D. Bohm, 1975).
The science of the future will include the vigorous methodology of science as well as an integrated understanding of the quantum reality. Electrogenetic science is an excellent example of how these two halves are becoming a whole. The holistic perspective involves the
understanding of bioenergy, homeostasis, and the integrity of the whole. Each individual person is considered a unique ecological system, vitalized and regulated by bioenergy. Over the past twenty-five years, there has been increasing Western interest in the holistic studies and Eastern medical approaches, such as acupuncture, Chinese medicine, Ayurvedic medicine and homeopathy. These "old" medical systems are each based on the bioenergetic nature of diagnosis and treatment. In health, the bioenergy of the patient is balanced and strong. In disease, an interference or weakness overcomes the normal vibration rate of the bioenergy, causing distortions in the energy field. These are called patterns of disharmony and are unique characteristics of bioenergetic medicine.
A new language is developing in the sciences to understand energy production, transfer, blockage and dissipation within the human body - at the level of individual cells, at the DNA level. Thanks to Dr. Garnett and his colleagues, there will soon be an integrated scientific understanding of "energy", and the lines of demarcation between Eastern and Western medicine will disappear even further
Acupuncturists are currently using POLY-MVA to enhance the flow of energy or "chi".
Once they understood that POLY-MVA is a bioenergetic catalyst for the transfer of energy, these innovative practitioners found that acupuncture energy transfer is enhanced when they use acupuncture needles dipped in POLY-MVA or when diluted POLY-MVA is injected into acupuncture points. Energy transfer is sustained for significantly longer than the time for which the needles are inserted. Robert D. Milne, M.D., feels that further research will document the salutary effects of this special use for POLY-MVA.
6. Clinical Research on Poly-MVA along with the Forsythe Immune Therapy (FIT)
Earlier in this book, I had commented on the design of the clinical outcome-based study done in cooperation with AMARC and Dr. Albert Sanchez in regard to studying survival rates, longevity and quality of life issues on patients receiving low-dose chemotherapy along with Poly-MVA and the FIT protocol. The study then and now measured survival rate in terms of (1) complete remission, which refers to no measurable disease; (2) partial remission, which refers to greater than 50% reduction in all measurable tumor parameters; or (3) stable disease, which is still an acceptable remission but less than 50% and no progression of disease.
The study included all patients who survived over one month from the time of my treatment, and who had measurable parameters, and who were designated as Stage IV patients with distant metastases. Follow-up studies were done on the patients every three to six months, with office visits and further booster therapy if needed. Monthly blood tests, including CBC, tumor markers, and appropriate scans were also done on patients to ensure a correct prognosis was obtained. High-dose radiologic procedures were avoided, especially CAT scans and PET scans in order to prevent the patient's immune system from being harmed by high-dose radiologic procedures, sometimes up to 600 times the radiation dose of a plain chest x-ray. Instead, patients were given the option of taking plain x-rays, MRI's, ultrasounds, or thermography.
Careful follow-up on these patients was obtained by calling patients regularly, reporting their labs to them, having them back for follow-up visits and studies, and carefully recording their degree of remission. All expirations were counted, even if patients died of other causes.
7. POLY-MVA: Research Evidence
This chapter summarizes the laboratory research that has been done to explain POLYMVA's apparent effectiveness in prevention, supporting health and healing cancer.
Oncological surgeon Rudolf E. Falk presented the first report of clinical studies of POLY-MVA at the Adjuvant Nutrition in Cancer Treatment Symposium in March 1994. In his work at the University of Toronto, Dr. Falk administered POLY-MVA intravenously to ninetyfive patients. The cancers from which these patients suffered included cancers of the breast, lung, colon, rectum, prostate, pancreas, ovary, skin (malignant melanoma), and brain. Ninety percent of these patients had failed to improve after undergoing virtually all available therapy.
During their experimental treatment with POLY-MVA, they received moderate doses of chemotherapy. Under normal circumstances, 20 to 60 percent of such patients would only survive an average of another six months. However, nine months after initiation of intravenous POLY-MVA, 90 percent of these patients were still alive.
ROUTE OF ADMINISTRATION
POLY-MVA is most often taken orally, as it was designed to be used. Does POLYMVA have to be given intravenously to have the effect described in Dr. Falk's report? The research show that each tool has its place. You can simply raise the concentration in the blood to higher levels to saturate and support the tissues. We know that taking the supplement version (as a liquid mixed with water or juice) is effective as well, we like both. Some physicians who offer POLY-MVA therapy to their patients choose to give it intravenously, specifically when they are
treating end-stage cancer patients. Many are also combining intravenous POLY-MVA with oxidative therapies such as ozone therapy, IV Vitamin C and hydrogen peroxide therapy. I have reported in my Poly-MVA study a 20 percent efficacy rate in Stage IV adult cancers, being given 40 mL per day through intravenous routes, then those receiving oral doses only of 40 mL per day orally in divided doses.
Patients who take it orally, which includes most of the patients who have tried it, report good results. Intravenous use moves the nutrients to the cells more quickly and the research is there to support widespread intravenous use of POLY-MVA. The LAMC’s were designed by Dr. Garnett for oral use and it shows the uniqueness of the complex and formulation that it can be used topically, rectally, nebulized, IM and locally to most tissues
POLY-MVA AND GLIOBLASTOMA
Pharmakon Laboratories performed animal studies to determine the safety and effectiveness of POLY-MVA (LAMCs) in the treatment of glioblastoma, a fast-growing and highly dangerous brain cancer. At the beginning of the study, glioblastoma tumor cells were injected into the scruff of the neck of Swiss nude mice. When tumors had grown to 200-400 millimeters in volume, the mice were divided into eight groups of ten. Four groups were given daily intravenous doses of either LAMC or placebo; four groups were given intraperitoneal doses (tube feeding) of eight LAMC or placebo. Those who were given LAMC received doses of 1.5, 1.0 or 2.0 milligrams per mouse for a total of four weeks, and tumor volume was monitored throughout. Mice that died were dissected and tumor volume was compared between groups. Not surprisingly, the mice that received the LAMC had significantly reduced growth of the glioblastoma tumor cell line. All of the intravenously treated mice showed significant reduction
in tumor size compared with placebo. Of the mice given LAMC through tube feeding, dosages of 1.0 to 2.0 milligrams per mouse - a dose comparable to that used in humans with cancer - had significant effects, shrinking tumor size.
Frank Antonawich, Ph.D., a past neurobiology professor at the State University of New York at Stony Brook. Dr. Antonawich's research on cancer cells, while at SUNY Stony Brook, involved studying the safe and effective actions of POLY-MVA on brain and breast tumors. His team investigated the relationship between the degree of anaplasia (regression of specialized function) of malignant cells and the effectiveness of the LAMC Complex. They observed that more aggressive tumors seem more responsive to the LAMC, since they are more anaplastic and rely more heavily on anaerobic metabolism. Metabolic dysfunction, related to hypoxia and subsequent adaptive gene responses, renders some cells resistant to traditional chemotherapeutics but sensitive to the metabolic modulation of LAMC
Dr. Antonawich's findings have been further substantiated by KGK Synergy, Inc., an independent laboratory in Canada. In conjunction with The Foundation for the Advancement for Cancer Research funded KGK Synergy to conduct additional assays on LAMC to confirm its effectiveness in various cell lines. POLY-MVA was effective on several cancer cell lines, including melanoma, liver, lung, breast, prostate, colon, astrocytoma and glioblastoma.
In results similar to Dr. Antonawich's findings, the responsiveness of each of these cell lines varied based on their degree of anaplasia. For example: the Grade 1/2 brain tumor (astrocytoma) began to exhibit cell death 48 hours after LAMC exposure, with significant toxicity apparent within 72 hours after exposure. In contrast, a Grade 4 chemo- and radiationresistant brain tumor (glioblastoma) demonstrated evidence of cell death within 24 hours. These
experiments are important to consider, since LAMC appears to demonstrate its effects as a metabolic modulator. Dr. Antonawich and KGK's data help to explain why treatment times will vary based on the type of tumor studied and the tumor's characteristics (i.e., how quickly it replicates, its degree of anaplasia, and its location).
The largest integrative cancer investigation of LAMC supplement was conducted by Dr. Greg Ogilvie at California Veterinary Specialists. This was an open-label, veterinary oncology program with over 900 dogs enrolled, since its inception in January 2004. Patients received the LAMC supplement (Poly-MVA) s part of their chemotherapy, radiation and/or surgical protocol, at a dosage of 1.0 mL/5 lbs. p.o. twice daily (equivalent human dose of approximately 8 tsp.).
The LAMC seemed most effective in the cases of solid tumors (i.e., soft tissue sarcoma, hemangiosarcoma, mast cell, transition cell carcinoma, lung, anal sac carcinoma, renal carcinoma, squamous cell carcinoma, fibrosarcoma, melanoma, meningioma, neuroblastoma, and mammary adenocarcinoma). Some of the most effective findings were apparent in the osteosarcoma patients. The etiology of osteosarcoma in large dogs is considered identical to the disease progression in humans. While in canines the "standard of care" is limb amputation followed by chemotherapy, in human patients’ limb-sparing surgery following tumor excision is performed (Ogilvie and Moore, 2006). In this open-labeled study, integrative LAMC support (LAMC + amputation) improved the animals' median survival time 62% (103 days more) compared to surgery alone (n= 11 and 162, respectively). When LAMC was added to the chemotherapeutic regimen (carboplatin + doxorubicin) the dogs exhibited a 27% longer median survival (79 days more) (n= 32 amputation with chemotherapy; n= 17 amputation + chemotherapy + LAMC). Furthermore, there was no significant difference (p= 0.30) in median survival time between dogs treated with amputation + LAMC versus those that were treated with
amputation + the "standard of care" chemotherapy. (See the following graph:)
It is important to note that following LAMC complementary support, chemotherapeutic animals demonstrated improvements in various objective parameters (i.e., weight, anemia, liver and kidney function). In addition to these enhanced clinical parameters, a subjective owner quality of life survey resulted in an 86% improvement following the addition of LAMC supplement adjunctive support.
While Poly-MVA has been commercially available since 1994 with an excellent safety record, in 2009 a formal university dose-escalation safety study was conducted for the FDA in preparation for a glioblastoma study. Currently, this major research university is conducting a Phase I/II Poly-MVA study on glioblastoma patients. Results are expected at the end of 2013. In addition, a Multiple Myeloma IND study is being started at another research university. Those results should be available in 2015.
Formal, peer-reviewed cancer evidence on the clinical efficacy of LAMC and the strong safety data justify its use as an adjunct cancer treatment. The extent of LAMC's effectiveness or what agents may be used in conjunction with it to have an optimum effect, are unknown at this time because of the multiple variables associated with this disease and the need for further
research, which continues at this writing.
HOW SAFE ARE POLY-MVA AND POLYMVA?
POLY-MVA has been available since 1994, and over 20,000 patients have purchased or been given this product. Garnett-McKeen Laboratories has not received any reports of adverse effects with POLY-MVA from any of these patients. No letters from the FDA or state medical boards have been received about the product.
The results of toxicology studies in animals show that LAMC and POLY-MVA are very safe and nontoxic. No deaths or signs of organ damage occurred in test animals that were given extremely high doses. It was concluded that the LD50 (the dose lethal to 50% of test animals) of LAMC exceeds 5,000 milligrams per kilogram of body weight. At the highest dose in toxicity studies, which is hundreds of times higher than the dose used in humans, no clinical signs of toxicity or tissue damage were found. The average human dose is 6 milligrams per kilogram of body weight per day. With intravenous doses of 15 mL/kg (with the drug containing 25 mg of Lipoic Acid Mineral Complex per milliliter), some negative changes in animals' behavior was seen, along with a change in the color of their urine. Still, when the animals were dissected and examined, all organs were clean - no damage was found. The Ames test, the gold standard test for mutagenicity (the ability of a substance to alter DNA in a manner that could lead to cancerous changes) has showed LAMC and POLY-MVA to be completely antimutagenic.
The only risk factor that has been observed with LAMC in high doses is in patients with significant cancerous lesions in the lungs who are at risk of pleural effusion (collection of fluid in the lungs). Several cases have been reported in which high dose LAMC was administered to such patients, and the fluid in their lungs increased, so dosages were cut in half and then slowly
increased as the patient improved. The available information on LAMC's action indicates that this may be the result of a "die-off" of malignant cells, which can cause a variety of unpleasant symptoms as the body works to eliminate them through the detoxification pathways. Patients who fit this description should be closely observed while using POLY-MVA. A reduction in dosage may be required until the effusion clears up and to open up detox pathways.
The Phase I safety phase of the LAMC study (DESSTINI), was completed at the Department of Neurology at the State University of New York at Stony Brook in 2009. This study was granted an IND by the FDA and was a dose escalation (2 tsp., 4 tsp. and 8 tsp.) safety study in normal patients, prior to the initiation of an integrative cancer support protocol. No SAEs (Severe Adverse Events) were attributed to the product. The following AEs (Adverse Events) were considered either possibly or probably related to the study compound: nausea, vomiting, diarrhea, cramps, and aversion to the taste.
Most cancer patients report an improved quality of life when integrating LAMC to their treatment protocol, regardless of protocol. This is due to the ability of the LAMC supplement Poly MVA to provide energy at the Mitochondrial/cellular level. A Palliative Care Study was conducted by the Indian pharmaceutical company CIPLA. Patients took the LAMC supplement Poly MVA for 24 days (2 tsp per day), followed by a 12-day clearance period. The following parameters demonstrated statistically significant patient improvement: Cognitive Functioning, Emotional Functioning, Social Functioning, Fatigue, Sleep Disturbances, and Appetite Loss. Recently a Multiple Sclerosis-associated fatigue IND study was completed at Stony Brook University Medical Center. Each patient took 4 teaspoons per day for 6 weeks. The patients were tested at their baseline visit and at the end of 6 weeks using three Multiple Sclerosis Fatigue Scales (Fatigue Severity Scale (FSS); PROMIS Fatigue; Multiple Sclerosis Fatigue Impact Scale (MSFIS)). There was a statistically significant decrease in fatigue reported with each scale, leading the Principal Investigators to conclude that the product was “well tolerated and was associated with a clear reduction in fatigue severity and fatigue impact”.
8. True Stories of Cancer Survival with POLY-MVA
This chapter contains true stories from real cancer patients who have used POLY-MVA. These stories have been collected from the POLY-MVA Survivors' website, from the Townsend Letter for Doctors & Patients magazine, and from the files of the Association for Wholintegral Medicine, Inc.
Almost every person whose story you will read here made drastic changes in his or her diet and lifestyle, and many used various other nutritional supplements, in an effort to heal themselves from cancer. The common denominator and the long-term survivorship is that they have stayed on the LAMC since they started their programs and in their stories of renewed health, however, is the use of POLY-MVA that many times was the game changer and turning point for them. Some had been using other natural methods to try to heal their cancers, but they did not experience significant pain relief or disease regression until they added POLY-MVA to their regimen.
In several cases, the patient's success with POLY-MVA and other holistic therapies has been considerable enough to convince even skeptical mainstream medical practitioners to investigate this safe and unique complex for health and healing.
HARRY QUICK, D.V.M.
After being diagnosed with adenocarcinoma in 2002, Harry Quick, D.V.M., had a cancerous lesion removed from beneath his left armpit. Doctors recommended radiation treatment, but Dr. Quick refused and sought out "an alternative, less destructive protocol". He used a Japanese product called MGN-3 to enhance the activity of the immune cells responsible for singling out and destroying cancerous cells. Unfortunately, within two weeks after his surgery his tumor returned, and a month later it was the size of a golf ball. He knew he needed to do something, and fast.
After some thorough research, Dr. Quick determined that he needed to make a lot of lifestyle changes, including modifying his eating habits and avoiding toxins. He controlled his stress level and began to exercise regularly, and he made a greater effort to participate in his community. He also took massive doses of intravenous vitamin C. For three hours a day he sat with an IV line in his arm, dripping 75,000 milligrams of vitamin C into his bloodstream. By June's end, his tumor was the size of a pea, but he suspected that the vitamin C treatments were dehydrating his body and he wanted to seek out something else. He then began to use POLYMVA.
After two weeks of taking 12 teaspoons of POLY-MVA a day, Dr. Quick sent his blood plasma to a lab for an AMAS test, which is used to measure anti-malignant antibodies, a marker of whether the immune system is actively destroying cancer cells. For the following thirty days he took 6 teaspoons of POLY-MVA a day along with Coenzyme Q10, MGN-3, a probiotic supplement, multiple vitamins and minerals, and a diet of organic vegetables with some chicken and fish, after which further tests showed him to be in remission, and he was feeling much
improved. After a final surge in a subsequent AMAS test (a common result of cancer cell "dieoff"), a PET scan and a final AMAS test in November showed that his body was free of cancer. He spoke with Dr. Sanchez in June of 2006 and is still doing well.
MARYLIN CLARK-KOENING
In April of 2004, at the age of 68, Marylin entered a large imaging center for a routine mammogram with the same apprehension most women feel until they receive the all-clear report. She was told to wait and not to dress after the mammogram as the radiologist might want more views. In an e-mail to Dr. Sanchez, Marylin told her amazing story:
The wave of anxiety jolted me like an electric shock, and I steeled myself for the worst. An ultrasound was done immediately and the technician called for the doctor, who looked at the images and exclaimed as if I were not there: "It doesn't look like a cyst to me. I am most concerned with the shadow area." His words seared like a shot in the night beyond my physical being and seemed to pierce my very soul. There and then I knew what I feared most. Cancer!
The surgeon said I would need a "cut biopsy". My request for a sentinel node biopsy was denied for reasons I can't recall. The growth was small, so it was removed entirely during the biopsy procedure. A week later I received a call telling me it was indeed a malignant growth, and I would need further surgery and a wide-angle lymph incision to explore the "shadow" area. The surgeon said I would have to agree to five weeks of beam radiation of the left breast after surgery.
I declined radiation and advised the surgeon that I also wanted another opinion. He then said it would be malpractice for him to do the surgery without my consent for radiation. I was
promptly "fired" by the surgeon.
I asked for the pathology and operative reports. To my horror, I saw the words "Invasive Ductal Carcinoma with margin involvement...tumor grade 3.3." This knowledge drove me to an emotional depth of despair and fear that I had never known. Literally, I felt mummified for three days and nights, fearing the conventional treatments more than death. God knows, I had had my fill of the poisoning aspects of conventional cancer treatments: initially, as a teenager watching my father die a slow and agonizing death from cancer; and years later, when I los a dear friend to breast cancer. Her spinal cord swelled during radiation treatments, and she suffered what no human should ever have to endure. She literally died from the conventional treatments. The memories of both victims were still fresh for me; I had had enough of the cut-and-burn route that gives no guarantees.
The next eight days were spent at my computer, 12 to 14 hours a day, using the Google search engine to try to learn as much as I could about alternative cancer treatments. There were over 2,000 sites. I prayed for guidance, begging God to help me. I could not choose herbs, teas, or Indian tree bark. "Isn't there some alternative with a scientific basis somewhere out there?" I kept asking myself. Finally, on the sixth night, POLY-MVA came up in a search.
I read about Dr. Garnett, the inventor of POLY-MVA, and how he was determined to restore the normal, rather than poison the abnormal. I learned that POLY-MVA only targets the cancer cells. With those words, hope took the place of abject fear.
Relief abounded when I read that Poly-MVA contains a natural, nontoxic anti-cancer agent. The basic science was there, the testimonies were impressive and numerous, and the clinical science was well underway. My decision was made.
When relatives and friends learned of my decision to take a road less traveled - an alternative treatment - the pressure of their fears and tears was overwhelming. We found a place on the Oregon Coast where we hid out for three months. Our focus centered on an allnatural diet and on feeding the spirit with meditation, visualization and relaxation tapes. I learned from my Internet search on alternative sites that cancer is fueled by sugar, so I took sugar out of my diet completely. Diligently, I followed the Four Corners plan, supplementing with a liver cleanser, a pH moderator, an immune function enhancer and, most importantly, Coenzyme Q10. The CoQ10 significantly enhances the active complex in POLY-MVA.
Each night, I fell asleep reading Mark Olsztyn's and Gracie Todorczuk's testimonies and almost memorized Dr. Milne's book. They gave me strength and commitment to keep on keeping on. September 2004 came quickly it seemed, and we returned home to Nevada. Though feeling well, I did not know if my healing retreat had worked for me. Having been fired by the doctor, where could I go now? How could I get the tests necessary to monitor my progress? I had then completed four months of this product. Where to turn next?
Through the help of friends, I was able to get an appointment with the foremost breast surgeon in Las Vegas with impeccable credentials. This doctor was kind, but asked me if I knew that POLY-MVA did have FDA approval. He dismissed my alternative information, and he did an immediate mammogram. In his belief system, he could not conceive that I did not have active cancer. To my amazement, he did attest that I did not lose any traction over a six-month period, and the lymph nodes felt OK. "You are lucky because you are no worse," he told me.
He advised that another, less invasive surgery called Mammosite was necessary. "I will clean out the area by doing a partial mastectomy and a balloon will be placed in the area. You will have only targeted, minimal radiation to that precise area for five days, 10 minutes twice a
day. A special machine will place a radiation seed into the balloon area only, not radiating the entire breast". This sounded so much better than the plan of the first surgeon. Certainly, I was relieved that the LAMC worked in the sense that I was no worse... but even I now believed I still had cancer.
The surgery was performed November 9, 2004, almost six months to the day after the first biopsy. By this time I had taken LAMC for five months. The sentinel node biopsy was negative and the Mammosite surgery was completed. Three days later, the biopsy of the breast tissue excised from the partial mastectomy was returned with a lengthy report from the pathologists. It was obvious by the length and description of the report that they looked long and hard to find the cancer that, in their opinion, had not been treated for the past six months.
EVERYTHING CAME BACK NEGATIVE. THERE WAS NO TRACE OF MALIGNANCY.
I was in shock. I had a balloon in place with tubes hanging from my breast, ready for the five days of targeted radiation. I asked my breast surgeon, who had been so accommodating to see a patient on an alternative therapy, "Why do I need radiation if the cancer is gone?"
He replied, "This way, it will never come back. Just do it Marylin." I did have the five days of targeted radiation; it was not a big deal after all. The balloon and tubes were then removed.
With the realization that I did not need the second surgery nor the radiation, I decided to put this experience behind me. While my surgeon would not let me discuss the LAMC with him prior to my radiation treatments, the radiation oncologist, a vibrant young doctor with a warm manner toward his patients, did amaze me. As I followed her down a long and narrow hall, we
passed several patients who were obviously at various stages in their treatments. Four had their heads covered and all looked down at the floor when I passed. Chills ran down my spine.
She ushered me into a small office, closed the door behind her, and whispered, "Marylin, what did you do... did you take herbs?" I then proceeded to tell her about LAMC. She did not comment but smiled in a gracious manner. The next day, I dropped off a package about LAMC for her information. Last week, eleven months since the ominous mammogram, I saw this oncologist again for a checkup. She examined me and said, "You are doing just fine. You don't have to return to see me for six months."
The recommendation for those in remission is one teaspoon a day of LAMC; I am choosing to stay on three teaspoons a day, as well as The Four Corners Protocol. We're maintaining our commitment to an organic diet. My pathology reports before and after are available to interested parties. I can be contacted at: marikonig@aol.com
GRACIE TODORCZUK
This 42-year-old breast cancer survivor discovered POLY-MVA very shortly after her breast cancer diagnosis on January 24, 2001. Her 2.0-to-3.0-centimeter invasive infiltrating ductal carcinoma was removed with a lumpectomy on February 20, 2001. She was told that there had been a small area of lymph node invasion. At the time of her surgery, she had been taking POLY-MVA for fifteen days, and a preoperative ultrasound showed that her tumor had shrunk.
Ms. Todorczuk also followed a strict holistic program, starting with her diagnosis. Since her lumpectomy, all followup exams have shown her to be cancer-free, without subjecting herself to chemotherapy or radiation. After getting yet another clean bill of health at a followup
with her surgeon, the surgeon decided to take a careful look at the program that had enabled his patient to go from a Stage III cancer to cancer-free without toxic therapies.
JANICE BARSBY
In an e-mail to Dr. Albert Sanchez, Sr., Janice wrote:
After reading some of the thing’s others have gone through, I feel very fortunate.
I am a survivor of Stage IV (end stage) Multiple Myeloma (bone cancer). This form of cancer effects the bone marrow where your red blood cells are made. The red blood cells cease to be manufactured and your hemoglobin just drops till you have no red blood cells left.
This cancer also eats away your bones. Pain is so intense it cannot be described. I slept sitting in a chair for two months (before diagnosis) as I could not bear the pain of lying down on my side or back.
I guess my story started in 2003 when my husband became ill. He was misdiagnosed and I had about three hours' sleep a night for three months. He had diverticulitis, acute, with a bowel blockage, and the pressure caused extreme leg and back pain as it pressed on his femoral nerve. After finding the right doctor, he had 10 inches of his colon removed, which solved that issue. Unfortunately, his heartbeat had become irregular, and we spent six months correcting that. It was a stressful time. I was bitten, during this time, by a Brown Recluse Spider, and did not realize what it was and that went untreated. (Look up the symptoms of a brown recluse spider bite; they are similar to multiple myeloma).
In April of 2004, the discomfort in my legs and back accelerated, but with my husband having to have a second surgery, I put it on the back burner. I also had to host a convention of
600 singers (my Sweet Adeline Regional Singing Competition came to Boise)... talk about stress!
By September I could hardly move. I was in constant pain and exhausted. In July and August I visited the doctor, and on my second visit the doc found really abnormal blood work but just wrote it off. In September, same result, only the blood work was worse. I have a natural MD in Nevada; so, in October, when I had to get around on a rented mobile scooter, I went to see him, and he immediately sent me to an oncologist in Idaho. While waiting, I yelled at my regular doc, and told him I was dying and needed a blood transfusion. His reply: "I don't need another doctor telling me what to do!" I did get my blood transfusions and a week later met my oncologist, a lovely lady called Dr. Forsythe. She did a bone marrow test and told me I had multiple myeloma. Cancer! I just sat there and cried.
I will add here I am a retired Registered Nurse. My last position was to work for a world-renowned oncologist and open a unit for him in a major hospital. I also gave lost of chemotherapy! At the time of my diagnosis, I was 60 years old.
I agreed to have some radiation only to relieve the pain. I was started on enough painkiller to knock off a horse and was still in agony. This was the last week in October 2004. I was admitted to the hospital the last couple days of October, as I was a little delirious at times, in total kidney failure and just a mess.
Well, my dear husband Jim, had just been frantic over my diagnosis and turned to searching for a cure. He had just re-signed to Dr. Sinatra's natural healing letter, and the following week the doc presented information about POLY-MVA. My husband ordered it by overnight mail and as I was leaving for the hospital he gave me four teaspoons twice. I emptied a bottle of cola that I happened to have in the fridge and filled it with LAMC. I put it in my purse and off I went. I was prodded, poked, x-rayed, hydrated with IVs, and scheduled for dialysis.
Twenty-four hours later, the doc took another test and noticed my kidneys were better, and decided to wait on the dialysis. Each day they got better. (The fluids also helped.) Then she asked me why I thought my kidneys were improving; I said "I don't know" - but each hour I was drinking two teaspoons of LAMC! (I didn't tell the doctor or anyone, as I did not want it taken from me.)
Four days later I was sent home. They had already informed my husband I would not live. At this point I could only walk with help and could not lift my arms. My legs were swollen to three times their size and I looked and felt like I was 100. When I went home in four days, the docs were so surprised. I took the Four Corners protocol, CoQ10 and LAMC. My nausea and vomiting, from the radiation mostly, were so severe I could not tolerate too many extra things. Thanksgiving eve was my last blood transfusion. I was starting to regain my bone marrow.
The radiation nuked my white cells and platelets, so I quit after three weeks and said no more. I refused the chemo - the doc was not too happy, but she knew who I had worked for and understood that I knew too much about chemo to want to go there myself. There is no actual chemo that works on multiple myeloma anyway... so what's the point?
I did not eat any sugar; I lived on raw juice and cream soups. That was all I could keep down. I lost 40 pounds - I had been overweight, but it was scary to have my clothes falling off like they did. Fear was a companion, but with help I worked through that and I just knew I was going to get better. My Sweet Adeline group was a tremendous support every day!
I did daily biofeedback and imagery. Each month I improved and gained more mobility. The nausea and vomiting were the worst, as they left me exhausted. The hospital personnel, who were really good to me, had a big conference to put me on IV pain meds, but I told them that was
only for dying people. You could just see the look on their faces: "Boy, is she in denial!"
Christmas Eve I was hospitalized with a heart rate of 200. Turns out the radiation inflamed my heart so badly that it caused it to malfunction. I am still on heart meds, but it's under control.
I had some ozone and ultraviolet light therapy in January. This really gave me a boost, and I knew my spring I would be almost better. After six months of pain and suffering, thanks to LAMC, I started to get my strength back and feel better. My blood work greatly improved. My oncologist still can't believe it! In March my blood tests were normal, my HG being the best it has been in five years - yes, making my own blood cells like crazy! (My cancer was unusual in that it could not be tested with blood work or markers, but only through a bone marrow test. some of my natural docs thought it was brought on by infection.)
A bone marrow test in April of 2005 showed NO CANCER. The docs did not believe it; they sent the test for further analysis, which came back negative. I did lose six to eight of my spinal discs to the cancer and lost four inches in height. (I do not have osteoporosis.) I had an MRI, which showed some SMALL cancer lesions on my spine. I still had some back pain. As of this writing (6/25/05), my back pain has almost gone and I am standing straighter. I expect that my next MRI, scheduled in a couple of months, will show that the spine lesions are gone. I am eternally grateful to my husband who nursed me night and day and got me through this, and to God for sparing my life. Without LAMC, I am sure I would not be writing this today.
Please feel free to contact me at: buyersoutletmall@earthlink.net.
JOHN MERRITT
This 60-year-old stockbroker was diagnosed with Stage IV glioblastoma multiform in March 2000. This fast-growing brain cancer is notoriously difficult to treat. At Cedars-Sinai
Hospital in Los Angeles, Mr. Merritt underwent surgery in April 2000, followed by thirty-three rounds of radiation. His tumor returned, and he had a second surgery in which Gliadel wafers (small plastic discs that contain cancer-killing drugs) were inserted into the cancerous tissue.
An MRI at the end of October showed regrowth. Oncologists recommended the chemotherapy drug vincristine, but Mr. Merritt and his wife had found messages about POLYMVA at a brain tumor support group website and decided to try it first. He began to take POLYMVA in November 2000. Since that time, he has continued to work, play golf and travel. Mrs. Merritt reports that her husband has suffered no memory deficits - she even feels his memory has improved somewhat! An MRI from February 2001 showed that his tumor had decreased in mass. Six months later, John was doing wonderfully, living a full life with no restrictions. In July of 2002 he had another MRI that showed a mass, but it was stable. The doctor convinced John to try another chemotherapy and from that time his health diminished until his death in February 2004.
ODETTE GAUD
This young woman told her story in an e-mail:
I am 36 years old and I have two wonderful kids: a seven-year-old boy and a three-yearold girl. My partner and I live in the Azores, Pico Island, Portugal. My nightmare began in June of 2002, when we moved to the Azores from Cape Town, South Africa. I left family and friends behind; I could not speak Portuguese and I did not understand or even like the culture. I knew nobody. I hated it.
In November 2003 I went to the gynecologist for my yearly checkup, including a check of
the breast lump that I had carried around with me since the birth of my son. A needle biopsy came back benign. The doctor advised me to have a mammogram to make sure, which I did.
The doctor told me that the results were suspicious. I went home in a state; I knew that I was going to follow his advice and have the damn thing cut out. I did this against my partner Graeme's advice, but I was listening to nobody. On December 2nd, I went into the hospital and had a lumpectomy. On the 15th of December I got a call to go to the hospital and I received my results.
BREAST CANCER - INVASIVE DUCTAL CARCINOMA - DEATH SENTENCE.
The cancer had spread past the actual sample that was cut out and used for a diagnosis. His advice: we have no time to waste; the breast has to be chopped and the lymph nodes have to be removed to see if it has spread to other regions. Once he had disfigured me and cut away my feminine parts, he suggested huge doses of chemo and then radiation. With all this information he sent me home, telling me that he would wait for my decision.
My nightmare had begun. But little did I know that huge miracles were awaiting me.
The first in a series of events to unfold which would change my life forever: a guy from New York knocked on my door, in the middle of the Atlantic - don't forget, on an island that hardly anybody in the world knows about. He was looking for property in the Azores to set up a little health farm. He was a naturopath. We just happen to sell property here, too. Not very successfully, but we try. We told him what had happened to me and he spent three days with me explaining to me what had to be done to change my blood work to a clean slate. He gave me a protocol, but we were so broke that I could not afford to buy the supplements and stuff on his list.
Not only was I penniless, but the Azores never had a single health shop on its shores. To make matters even worse, I had to consume this raw fresh diet of green vegetables. All that was
available to me was cabbage, wild spinach and parsley, at exorbitant prices. I would have to get all my supplements from the USA. No money meant no medicines.
The most amazing thing that he did was to take a blood drop and put it on a microscope slide. He let it dry, and from it he was able to tell me exactly what was happening to me internally. We soon discovered that due to amalgam fillings and silent infection in one of my root canals, and of course the fact that my immune system was non-existent from all the stress of immigrating, my body had allowed the cancer to grow.
I cannot find the words to explain to you the panic, the tears, the thoughts of dying, of leaving my kids to grow up by themselves, the panic attacks, and probably the worst, the stress it created between my partner and me. I told my doctor to please give me until February 2004 to make up my mind as to what I wanted to do. He also told me that my chances of survival after doing all the conventional approach was 50/50. I also did not really understand how and what kind of diagnoses I had. All I knew was that I had breast cancer. I did not know anything else, as I could not really understand what the doctor was telling me. Little did I know that doctors love to use scare tactics on their patients to push them to make a decision. This was what made me fire my doctors. I decided to take responsibility for my health.
Once I had made my decision, my stress was made worse by my wonderful, caring family back home, sitting on the phone, spending a fortune trying to get me to change my mind. It almost worked. But soon I realized that they were just very scared for me and the only way they could make themselves feel better was to try and get me to do the conventional thing that everybody else does. Even if this way led, in most cases, down the line, to death. I have made everybody around me see things differently. They still think I am crazy - especially the people
living on my island. But I withstood the storm and have even got a very few people coming up to me to ask me about how I did it. That, for me, was a success.
I began to spend at least five to six hours a night on the Internet. I hooked up with so many wonderful people and groups. If I decided to go the natural way, I had to know how. I spent so much time on the Internet that I basically bankrupted us. I would get a phone bill of two to three hundred Euros a month. This also meant that I could not get my medicines. To add to the stress, Richard (the neuropath from New York) took another blood test and told me that the cancer had spread to my lymph nodes and to my uterus.
To start the healing process, I had to clean up my mouth - have the amalgams removed and get rid of the infected root canal. Once this was done, Richard could immediately see the difference in my blood sample. I also had to drink 32 ounces of green vegetable juice and eat raw, live foods. I could not do this; I cheated from almost day one, although I knew that if I did not follow this, a painful death was the final outcome.
But I was still in store for some huge surprises. In my Web wanderings, I stumbled upon Bill Henderson's Web page. I asked him to help me put together a protocol that cost very little cash. He then informed me that he had just interviewed a gentleman by the name of Al Sanchez, and that Al Sanchez was giving away a year's supply of POLY-MVA. All I had to do was be part of the research he was conducting. Bill Henderson gave me contact numbers, and before I knew it I was part of the tests being conducted. For me, this was a blessing as I would never have been able to afford a single bottle. I also became part of the LAMC support group, and I found out about the Four Corners Protocol. Needless to say, it took me ages to get my protocol together with a lot of help from a lot of wonderful people. But it happened.
I took the intense protocol everyday for three weeks. I chose not to eat solid foods so as
to allow my pancreas to rest and manufacture enzymes so that these enzymes could repair the damaged tissue that had been damaged by the cancer. This was the hardest three weeks of my life. I LOVE FOOD! When the three weeks were over, it had paid off. Now I know that I will always maintain a diet of NO SUGAR, mostly raw, lots of vegetables, no dairy, no white flour, extra-virgin olive oil. I will always take the LAMC and the Four Corners Protocol (finances allowing): MSR-3, CoQ10, coral calcium, a liver cleanser, and (most importantly) LAMC. The wonderful result is that I have brought my tumor markers down into normal ranges.
Another part of my healing was being able to forgive and let go. I had to clear my inner thoughts that were in turmoil. I had to learn to love the island I lived on, and forgive Graeme for bringing me here. I had to learn how to enjoy my kids. I had to learn how to enjoy life. That was perhaps one of my hardest lessons to learn.
MAUREEN ARNETT
Despite having always been health-conscious and having no family history of cancer, Ms. Arnett had to have her cancerous ascending colon and several lymph nodes removed in May 2002. She recovered quickly from the surgery and was advised to undergo chemotherapy, which she refused. Instead, she began taking POLY-MVA immediately after surgery, starting with 8 teaspoons a day and dropping down to 4 teaspoons a day after two months. She also took several other supplements for liver detoxification, including freshly pressed wheat-grass juice, a liversupport supplement containing milk thistle, artichoke leaf, dandelion root, turmeric, amino acids, MGN-3, and Coenzyme Q10. She also followed a diet tailored to her blood type. Her follow-ups have revealed no cancer anywhere in her body, and she reports feeling great and being active
every day.
DANIEL RICKER
Daniel's parents, Diana and Larry, tell this story about their son:
Daniel is a very active seven-year-old who enjoys rock-climbing, biking, swimming, and riding his scooter. He even tried "sheep riding" at a local rodeo. He also enjoys playing and learning, and he is a good friend.
Daniel had always been right-handed. Then he began using his left hand for writing. We thought maybe he really is left-handed. Daniel continued writing with both his left and right hand, switching back and forth. In May of 2002, during an eye examination, the doctor noticed that Daniel was unable to follow an object upward, had no reaction to light, and tilted his head to the right when he walked. These symptoms prompted him to order an MRI before writing Daniel an eyeglass prescription.
After researching Daniel's symptoms on the Internet, we suspected the horrifying reality that our son may hae a tumor. So, we brought him to a local Emergency Room requesting a CAT scan of his head. The results came back within an hour, and we were told that our son had a brain tumor located on the midbrain, about two inches behind his eyes. An MRI confirmed the tumor was located in an area that surgeons considered a very dangerous place to operate, a place where breathing and heartbeat are controlled.
Rivers of tears flowed coast-to-coast when all learned of Daniel's illness. Many questioned how this could happen to a boy who looked so healthy and was filled with so much energy. He had just graduated from preschool.
A neurosurgeon on staff at Phoenix Children's Hospital offered some hope through
Stereotactic Endoscopic Surgery. Daniel began visiting with a Child Life Specialist to learn why he was in the hospital. On the morning of his surgery, all Daniel could say was "Call my doctor, I want to go to surgery." Within two hours of this miraculous surgery, Daniel was speaking and even regained his appetite, requesting spaghetti, pancakes and peaches.
Daniel was showing excellent signs of recovery a month after his surgery, but then a followup MRI showed significant re-growth of his astrocytoma tumor, almost to its original size. We were told that Daniel was going to die and to get him into radiation treatment right away.
Daniel had six weeks of radiation treatment - a difficult time for all of us. Six months later, we learned of LAMC through Gary Matson. Gary was our lifeline then, bringing compassion, understanding and hope to our lives as we tried to only imagine what the near future held for our little boy. Through it all, we learned a new way of life. We live each day to see Daniel and his sister Rachel smile, and to see others smile.
Eighty percent of children with brainstem tumors die within two years. Our son is a survivor: a LAMC survivor. We are here to tell you that Daniel is alive today because God led us to AMARC, Dr. Sanchez, and Gary and Tim Matson. These are men who live their lives to make cancer patients and their families smile. It's because of the pain they endured with losing a loved one to cancer that they have dedicated themselves to serving others by providing information about the benefits of using LAMC.
Today, Daniel's tumor is inactive due to necrosis. There has been "no growth" since he began taking LAMC. The post-radiation side-effects are more manageable because of this supplement. He takes 5 mL four times a day with Q-Gels (CoQ10) from AMARC. Daniel continues to show remarkable improvement with rebuilding strength in his leg, arm and hand
through physical and occupational therapies.
Larry and Diana Ricker can be contacted via e-mail: RickerFamily1@yahoo.com.
JOSEPH WHITE
Joseph White had a stroke that caused partial right-sided paralysis in 1998. Later, he developed back pain so severe that he could not sleep, and in September 2001 he was diagnosed with prostate cancer that had metastasized to his hip bones. Radiation, surgery to remove the prostate, and chemotherapy were recommended, but Mr. White decided against all of them. He treated his pain with painkilling medication.
In November of that year, he received some literature on POLY-MVA. His PSA was 225 by then - a score indicative of advanced cancer. He took POLY-MVA for two months, and by January 15, 2002, his PSA had dropped to 5, and his pain had gone away completely. When his doctor saw these results, he was, in the patient's words, "utterly amazed" and "became a believer" himself.
KENNETH WALKER
This 67-year-old clergyman's story appeared in an article by Morton Walker, D.P.M., printed in the February/March 2003 issue of Townsend Letter for Doctors & Patients. Reverend Walker was diagnosed with multiple myeloma - a diffuse cancer that affects bones throughout the body - in March 2001. He had terrible bone pain in his head, ribs, spine, and elsewhere, and when he was diagnosed his physician’s found holes in his skull, the size of small coins. His oncology team informed him that without chemotherapy he would have less than three months to live. Multiple myeloma, reports Dr. Walker (no relation to Reverend Walker) in his article, kills
52 percent of patients within three months of diagnosis, and 90 percent die within three years.
Reverent Walker turned to POLY-MVA for support, and he was well enough to spend the late summer of 2001 sailing around Vancouver Island with his wife in their sailboat. Unfortunately, after 6 years taking Poly MVA Ken stopped responding to his thalidomide, was switched to revimid, but experienced horrible reactions to it and his cancer advanced. He lost his battle in Noevember of 2006, but credited much of his longevity to the use of POLY-MVA
THREE CASE STUDIES: PROSTATE CANCER
In a paper published in the Journal of Alternative and Complementary Therapies in August of 2005, Shari Lieberman, Ph.D., C.N.S., F.A.C.N., and James W. Forsythe, M.D., H.M.D., report on three patients with prostate cancer who used POLY-MVA:
. R.Z. was 73 when diagnosed with Stage IV adenocarcinoma of the prostate in January of 2001. His Gleason score was 6, and his tumor involved 25 percent of the right lobe and 15 percent of the left lobe. At the time he was diagnosed, his PSA was 7.8 and a bone scan showed 7th rib metastasis. CT scan of his pelvis and abdomen showed possible liver metastasis and liver cysts, with tumor nodules around his left ureter. He was rising four to five times a night to urinate, and he had trouble urinating through his partially obstructed ureter. R.Z. refused conventional treatments (radiation, chemo and surgery), and instead he began multivitamin/ mineral and herbal therapy (PC-RES, a Chinese herbal combination). He continued this regimen until May 2004, at which time his PSA had risen and fallen and ended up at 11. He added LAMC to his regimen, using 2 teaspoons four times a day, then reducing his dosage to 2 teaspoons twice a day after six months. By February of 2005, his PSA was consistently back down to 8.7. After being maintained on LAMC for 11 months, R.Z. remained physically and
mentally active, with good sexual function and libido. At the time of the study's publication, he was only rising two to three times a night to urinate, and he had unobstructed urine flow.
. J.C., aged 59, was diagnosed with adenocarcinoma of the prostate, with a Gleason score of 6 in September 2004. There was no metastasis, but he presented with difficult urination (dysuria) and blood in his urine (hematuria). He refused conventional treatment and began immediately on intravenous (IV) LAMC in November of 2004. Over the next three weeks, J.C. continued with a program of IV and oral LAMC, and he continued with 2 teaspoons four times daily after stopping the IV loading doses. As of March 2005, his PSA was 2.8 (down from a high of 5.6 in November 2004, following his first dose of LAMC). His prostate nodules were no longer palpable, and his hematuria and dysuria had resolved completely.
. M.O., aged 77, was diagnosed with Stage IV adenocarcinoma of the prostate in October 1996. At diagnosis, his PSA was 69.2, and his Gleason score was 3. He complained of back pain, and a bone scan revealed multiple bone metastases. He refused chemo, radiation or surgery, but he agreed to hormonal blockade treatment. In December 2003, he had been on Casodex and Lupron for 18 months; his PSA had fallen to 15.3 and risen again to 27.9.
Gynecomastia (breast development) and continued back pain caused M.O. to decide to stop the hormonal blockade. He began taking Zoladex (which reduces testosterone levels) and continued to take a multivitamin/mineral, fish oil, and an herbal supplement, which he had done since approximately the end of 2002. In February 2004, M.O. began to take LAMC, starting with 2 teaspoons four times daily for six months and then 2 teaspoons twice daily thereafter. His PSA fell to 0.4 and rose to 0.5, with a rise to 9 in February 2005. His back pain resolved and his performance scale was 100 percent at his last doctor's visit.
FURTHER PATIENT CASE STUDIES FROM DR. FORSYTHE'S LAST STUDIES, DATING
BACK FROM 2006
TO 2020, ALL OF WHOM RECEIVED POLY-MVA AS PART OF THEIR TREATMENT
Case #1, R.T.: R.T. is a 55-year-old, white, married female from Wyoming, with left breast cancer with spread to her left chest wall. She is now eight years in complete remission, having undergone a combination of Poly-MVA with the Forsythe Immune Therapy (FIT) Protocol. She is a rancher and originally refused all conventional chemotherapy. She underwent lumpectomy only, but she did not have radiation therapy nor hormonal therapy. She has had no disease progression during these eight years, and no spread to her lungs, liver, bones or brain. She has a 100% performance status and visits me once or twice per year on a continuing followup basis.
Case #2, I.D.: This 57-year-old, black female from Northern California was diagnosed eight years ago with Stage IV ovarian cancer with metastases to her lungs and mediastinum. She had received standard chemotherapy with Ataxene and a platinum-containing drug, which failed to put her into remission. She saw me in Reno, seeking alternative therapy. She was given PolyMVA with the FIT Protocol, and since this visit she has remained in complete remission, with no evidence of recurrent disease in her chest, mediastinum or elsewhere. She has a 100% performance status. She has not received any further chemotherapy or radiation therapy.
Case #3, C.C.: This 74-year-old, white widowed female, a retired night club owner and beer distributor, was seen by me seven years ago for advanced esophageal carcinoma with metastases to both her lungs, mediastinum and liver. She had been visiting my clinic between
two and three times per year up until several years ago, and because she has remained in continuous remission, she has been communicating with me from her home in Miami, Florida. She has done so well that she actually bought a condominium in Reno, to stay there while she was being treated. She has had no dysphasia. Her chest x-rays have been clear and her tumor markers have been normal. Her weight has been stable, and she has a 100% performance level.
Case #4, E.U.: This 65-year-old, married, white female from Washington state was diagnosed with Stage IV adenocarcinoma of the ovary greater than seven years ago. She had mild ascites and pulmonary metastases. She refused conventional chemotherapy but has been treated with low-dose oral therapy, along with our Poly-MVA and FIT Protocol. Her ascites has disappeared, and her tumor markers, CA-125, have returned to normal. She has a 100% performance status, and I continue to follow her for her tumor markers on a regular basis.
Case #5, E.D.: This 76-year-old, white widowed male, was diagnosed with a soft tissue sarcoma of his left groin seven years ago. He was treated with initial surgery and radiation, and he had a local recurrence which spread into his groin area and his scrotal sac. He was treated by me with Poly-MVA and out FIT Protocol, and he has been in a stable remission with no evident disease and with a 100% performance level.
Case #6, C.C.: C.C. is a 71-year-old, retired banker, with homes in Paris, France, and Manhattan, who came to my clinic four years ago with wide-spread bony metastases to his lumbosacral spine, pelvic bones and pelvic lymph nodes. He required high doses of morphine to control his pain, and his PSA level was elevated to 738 at the initiation of therapy. He was hormone refractory and, thus, he received no hormonal therapy. He was treated with our FIT Protocol along with IPT following chemosensitivity testing. His tumor marker, again which was initially 738, in four weeks dropped to 67. His pain medication requirements ceased, and he
continues to do well, in complete remission, being followed on the East Coast by a networking physician on Long Island. His performance status is 100%.
Case #7, P.N.: P.N. is a 51-year-old, single white male with adenocarcinoma of the appendix, associated with a gelatinous peritoneal fluid accumulation. The patient is now greater than seven years post-diagnosis. His acidic fluid became so severe at one point that he ruptured through an umbilical hernia, which was salvaged through abdominal surgery. He continues to do well and works full-time as a heavy equipment operator. His performance status is now 100%. He has required some low-dose oral chemotherapy.
Case #8, J.S.: J.S. is a 27-year-old, married, white female who saw me six years ago with Stage IV Hodgkin's disease involving her neck, mediastinum, and her peritoneal cavity. She refused conventional Hodgkin's chemotherapy or radiation therapy. She sought alternative therapy and was placed on our Poly-MVA/FIT Protocol, as well as some low-dose oral chemotherapy. During her tenure with me, she had a normal term pregnancy with vaginal delivery, and she gave birth to a normal infant, who had no signs of cancer. Her performance status is 100%.
Case #9, W.G.: W.G. is a 77-year-old, white, married male from Vallejo, California, with Stage IV prostate cancer with bone metastases. The patient refused hormonal or chemotherapy, and he has had no radiation therapy. His diagnosis was made via transrectal biopsy and he had a Gleason score of 7. He entered out Poly-MVA/FIT Protocol, and he has been stable and in complete remission for greater than six years.
Case #10, R.W.: R.W. is a 66-year-old, white, married female who is a casino worker from Las Vegas with breast cancer, metastasized to lung and bones. She refused conventional
chemotherapy or radiation therapy. Instead, she opted for our Poly-MVA/FIT Protocol and she has done well, over six-and-one-half years out, and she continues to work as a dealer in the casino with a 100% performance status.
Case #11, M.P.: M.P. is a 49-year-old, white, single female with anal cancer, squamous cell variety, who has been under my care for greater than five years. She presented after undergoing anal biopsy showing squamous cell carcinoma with metastases to her pelvic and inguinal lymph nodes. She refused conventional chemotherapy, radiation therapy and abdominal peritoneal resection with colostomy. Instead, she opted for alternative therapy and was placed on our Poly-MVA/FIT Protocol. She has done extremely well, with no evidence of recurrence in over five years. She has a 100% performance status.
Case #12, M.N.: M.N. is a 48-year-old, white, married female with metastatic thyroid cancer with bilateral pulmonary metastases. Her tumor was diagnosed as a follicular carcinoma with metastases to her lungs over six years ago. She has had bilateral pulmonary metastases, but she has done well without conventional radiation therapy or chemotherapy. She failed radioiodine therapy and, when seen by me in our Reno office, she was placed on our PolyMVA/FIT Protocol. She remains in complete remission with a 100% performance status.
Case #13, B.B.: B.B., a 46-year-old, white male attorney from the Bay Area, who was diagnosed with a malignant astrocytoma of the right frontal lobe over four years ago. He had an incomplete resection done at the University of California at San Francisco, with residual tumor being seen on his followup MRI studies. He refused conventional chemotherapy or radiation therapy. He was seen by me following his surgery and has since been on our Poly-MVA/FIT Protocol. He has maintained normal cognitive function and normal neurologic function. He functions as an attorney, and he is setting up an international corporation called "World Law".
He has also been helpful to me in starting a nonprofit foundation for financial help for my patients. He has a 100% performance status and continues to do well.
Case #14, G.T.: G.T. is a 69-year-old, white, married male from Bend, Oregon, whose wife was under my care for head/neck cancer when he, himself, developed wide-spread prostate cancer with metastases to his lower spine, causing epidural cord block at the L5 level. He presented with paralysis of the lower extremities. He underwent radiation therapy and surgical decompression of his lumbar spine. He was on-and-off hormonal therapy for the first two years, but he then opted for alternative therapy with our Poly-MVA/FIT Protocol. He has since been in stable remission. His neurologic losses in the lower extremities have completely disappeared, and he has a 100% performance status. He has not had any followup chemotherapy nor any further radiation therapy. He has not had any spread of the cancer to his lungs, liver, bones or brain.
Case #15, J.T.: J.T. is a 28-year-old, white male from Central Valley, California, with Stage IV colorectal cancer with liver metastases. He was diagnosed five years ago and refused conventional chemotherapy or radiation therapy. Instead, he opted for our Poly-MVA/FIT Protocol, along with some low-dose insulin-potentiated therapy following chemosensitivity testing. He has done well and continues in stable remission, with a 100% performance status.
Case #16, R.B.: R.B. is a 62-year-old, white married male, who is a chiropractor from Lodi, California. He was diagnosed with Stage II prostate cancer with metastases to his spine and pelvis. When initially seen by me, his PSA level was over 3,000. He refused hormonal or conventional chemotherapy measures, and he has not had any radiation therapy. Instead, the patient opted for complete alternative therapies, both with supplements and our Poly-MVA/FIT
Protocol. He has had some low-dose insulin-potentiated chemotherapy following chemosensitivity testing, and he has done well. His PSA level continues to decrease, and while it is not completely normal, he is not having any bone pain at the present time and he has been able to resume his full-time chiropractic practice, with a 100% performance status.
ADDITIONAL CASE STUDIES
Chip White, a researcher with the Association for Wholintegral Medicine (AWM), has more than ten years experience working with alternative approaches to cancer therapy. Mr. White has been engaged in an extensive analysis of patients who have used POLY-MVA. These case studies provide further insight into the breakthrough results that POLY-MVA, along with other lifestyle changes, has had on the lives of cancer patients.
Case Study 1: Glioblastoma
A male glioblastoma patient, 66 years of age, had convulsions and paralysis of his right leg and foot. Four days after starting POLY-MVA, he reported that his paralysis was gone and he could walk outside, water his lawn, and ride his stationary bicycle. Eight days after starting POLY-MVA, he called to report that his convulsions were occurring less frequently.
Case Study 2: Breast Cancer
A 56-year-old breast cancer survivor had metastases to her spine and right hip. She received a right hip replacement to gain relief from the pain her cancer had been causing, but she still had severe back pain. Within two weeks after starting POLY-MVA, she reported that her back pain had stopped and she was able to return to her job.
Case Study 3: Esophageal Cancer
Two patients with cancer of the esophagus required strong pain-relief medication. Both were terminal and had lost an extreme amount of fat and muscle. Patient A, aged 62, was in a hospital in Mexico and, although scheduled to start POLY-MVA, this patient only received laetrile (another alternative cancer therapy), and died shortly thereafter. Patient B, aged 45, received the POLY-MVA and soon reported increased strength and weight gain. This patient was still alive two years later.
Case Study 4: Multiple Myeloma
An Alaskan woman diagnosed with multiple myeloma sent a letter to the makers of POLY-MVA. She had received her diagnosis in April 1995, and after taking POLY-MVA for a little over two years, she was told that her blood tests and exams showed "no measurable signs of multiple myeloma carcinoma", and that she was "in total remission".
Case Study 5: Lung Cancer
Lung cancer is the leading cause of cancer death worldwide. Five-year survival statistics for patients with lung cancer are grim; only five to seven percent of these patients are still alive five years after diagnosis. In a paper by Shari Lieberman, Ph.D., C.N.S., F.A.C.N., and James W. Forsythe, M.D., H.M.D., the authors describe their experience using POLY-MVA as an integrative treatment in B.A., a 62-year-old patient diagnosed with advanced Stage IV non-small cell lung cancer in July of 2003. In January of 2004, she began to take a loading dose of eight
teaspoons of POLY-MVA per day, along with the chemotherapy drug Iressa. The patient had multiple metastases but continued to have a good quality of life while taking the supplement. She stopped taking the Iressa in November of 2004 but continued with a maintenance dose of four teaspoons of POLY-MVA daily, and she had no further chemotherapy until March 2005. She ended up responding to an older chemotherapeutic regimen of fluorouracil and mitomycin-C about two and a half years following her diagnosis, with her CT scans showing significant clinical improvement. As of July 2005, B.A. experienced some shortness of breath with physical exertion, but she was travelling and had a normal life, with no evidence of liver metastasis. The authors conclude that "the results of her most recent CT scan in January 2006, approximately two-and-one-half years after her diagnosis of Stage IV non-small cell lung cancer, were remarkable. Having no change in the CT scan would have been a desirable outcome. No one expected the level of improvement that was achieved."
The doses used in the above five case studies may have been lower than optimal; current research is being conducted with higher doses. Chip White also reports that colon cancer patients with obstruction report improvements after using POLY-MVA rectally POLY-MVA's solubility in both fat and water allow it to pass easily through membranes such as the one that lines the large intestine.
MANY MORE SUCCESS STORIES
The happy endings doesn’t end here. There are many other stories of people who have used natural healing modalities along with POLY-MVA to halt or reverse the spread of advanced cancers. Most of these people were told that they were giving themselves a certain death
sentence by refusing chemotherapy and radiation.
A 30-month outcome-based investigation by Nevada physician James W. Forsythe, M.D., H.M.D., lends further support for POLY-MVA in the treatment of late-stage cancer. Dr. Forsythe enrolled 212, Stage IV cancer patients for his investigation; all were volunteers who knew that they were using the supplement. The patients were given POLY-MVA for 30 months. Tumor parameters were measured with physical exam, x-ray, CT scans, ultrasounds, MRIs and PET scans, and with tumor markers including NMP-22, CEA, 19-9 and 5-HIAA. Of the original 212 patients, 75 completed the study, 39 discontinued the study, and 98 died during the course of the study. The results of the remaining 75 subjects were remarkable: 51% had a complete remission; 14% had a partial response, with at least a 50% reduction of the disease; and 35% showed stable disease, meaning that their disease did not progress, with up to 50% reductions seen.
In this study, the greatest impact of POLY-MVA was seen in cancers of the breast, lung and prostate. Eleven of the 19 cases of breast cancer had complete remissions, and 8 had partial remission or stabilized disease. Of the 8 patients with lung cancer who completed the study, 5 had complete remission and 3 had partial remission or stabilized disease.
POLY-MVA had the most significant effect on prostate cancer, with 12 of the 14 patients with the disease moving into complete remission, and 2 had partial remission or stabilized disease. Overall, the response rate to POLY-MVA was 56%. Dr. Forsythe found that an intravenous loading dose of POLY-MVA - in addition to the oral doses - improved outcomes by 20%. He concludes that "POLY-MVA appears to be a safe and effective natural food supplement for palliative assistance in Stage IV cancer patients, either with or without
concomitant chemotherapy... the safety profile is excellent, and there were no treatment-related deaths or any significant adverse reactions or negative interactions with chemotherapy or hormonal treatments." Dr. Forsythe continues to follow the progress of these patients. Further research is obviously merited.
Side-effects from the treatment were quite minimal. Less than 5% reported diarrhea; and fewer than 5% complained of mild shortness of breath with the highest dosage, which was a 40 mL dose. Fewer than 5% had transfusion reactions that were significant but not severe. (James W. Forsythe, M.D., H.M.D., "POLY-MVA Outcome-Based Investigation," www.drforsythe.com).
9. Using POLY-MVA for Nutritional Support and Protection
POLY-MVA is a promising nutritional approach to cancer, but it can be used to great advantage in people without cancer because of its unique LAMC complex and Mitochondrial mechanism. Research by Garnett-McKeen Laboratories, quality of life case studies, and others strongly suggest that POLY-MVA:
. Aids cellular energy production
. Supports liver detoxification (an important part of cancer prevention)
. Protects cellular integrity
. Chelates heavy metals (where harmful metals such as mercury, lead and
aluminum are bound up and excreted from the body)
. Has powerful antioxidant action, neutralizing free radicals within the cells and utilizing them to make energy; analysis of ORAC - Oxygen Radical
Absorbance Capacity, a measurement of antioxidant capacity - measures LAMC at 5.65; compare this with well-known antioxidants: vitamin A (ORAC of 1.6), vitamin C (ORAC of 1.12), vitamin E (ORAC of 1.0), and melatonin (ORAC of 2.04)
. Provides neuronal protection
. Enhances immune function (improves white blood cell activity)
Longevity and anti-aging research so far points to POLY-MVA's having a preventative effect and improving multiple blood panels. If you use a maintenance dose of ½ to 2 teaspoons, you would likely be protecting yourself against free radical damage, the growth and spread of abnormal cells before any masses are detectable. In a time when one out of three people can expect to have cancer at some point, it makes sense to improve your odds every way you can, and POLY-MVA and its nutritional support would be an excellent way to do so.
Free radical accumulation with inadequate antioxidant protection is implied in the causes and effects of many other diseases, including diabetes, Alzheimer's, dementia, heart disease, stroke and arthritis. POLY-MVA is a superior antioxidant that could help to prevent these diseases, as well.
Dr. Frank Antonawich has been investigating stroke and ischemia (interruption in blood flow) for over a decade at Stony Brook. His basic science studies have demonstrated significant protection from ischemia-induced apoptotic cell death using the LAMC compounds (POLYMVA and DNA Reductase). When POLY-MVA (LAMC) is administered immediately following a global ischemic insult, apoptotic death is reduced by 70%. This level of protection is not possible without both the stabilization of the electron transport chain (as evidenced by the maintenance of the mitochondrial permeability transition) and quenching of radicals generated upon re-perfusion (the re-entry of oxygen-rich blood into the area that has been ischemic). (Antonawich, et.al., Experimental Neurology, 2004).
Furthermore, since programmed cell death takes place over a number of days, POLYMVA administration can be delayed for up to 24 hours post-ischemia and still offer 50% protection. (Antonawich, et.al., Free Radical Biology and Medicine, 2006). Prophylactic administration of the LAMC supplement also has been found to protect against ischemia-induced cell death. Therefore, by modulating cellular energy, the LAMC compound is able to counteract the pathological effects of ischemia at multiple sites of action; it may offer hope to those suffering from TIAs (transient ischemic attacks - brief interruptions in blood flow), cardiac arrest with resuscitation, hypertension (high blood pressure), drowning with revival, anesthetic accidents, or cardiac ischemic conditions.
These ischemic scientific findings have led to the development of a double-blind, placebo-controlled study on Poly-MVA. Dr. Candice Perkins, Director of the SUNY at Stony Brook Stroke Program, was using Poly-MVA to reduce small vessel disease, a condition that occurs as a result of chronic hypertension (high blood pressure). High blood pressure decreases the diameter of the deep blood vessels in the brain, resulting in less blood flow to those critical
brain areas and subsequent ischemic damage. This study involved a clinical and radiographic (MRI) assessment of patients taking Poly-MVA daily over a three-year period. It had been put on-hold as a result of funding limits.
Additional collaborative studies are being conducted with Poly-MVA at the AMALA Research Center in Kerala, India. Peer-reviewed articles by Sudheesh, et.al., in 2009 and 2010 have demonstrated the beneficial effects of low-dose Poly-MVA on age-related decline of mitochondrial enzyme activity and respiratory chain complexes in rat hearts. Aged animals orally administered 0.05 mL/kg of Poly-MVA (equivalent human dose of approximately 1/2 tsp./day) had significantly enhanced Krebs Cycle activity (i.e., enhanced isocitrate dehydrogenase, x-ketoglutarate dehydrogenase, succinate dehydrogenase, and malate dehydrogenase activity). This LAMC-induced activity improvement was also significant at Complexes I & II of the electron transport chain. Thus, it appears that LAMC has the ability to shuttle energy to the aerobic respiration cascade to augment the generation of high-energy intermediate molecules within the Krebs Cycle, as well as directly boost the oxidative phosphorylation pathway responsible for the generation of ATP. We have recently confirmed these aged-heart findings in the brains of aged animals (Ajith, et.al., 2013). These energy findings have led to the development of a new human IND study assessing Multiple Sclerosisassociated fatigue at Stony Brook University in the Department of Neurology. Their additional work focused on the antioxidant benefits of LAMC and its subsequent protection from radiation damage. In their pre-clinical studies, DNA damage, mortality rates, and radiation-induced weight loss were all statistically reduced following acute administration of Poly-MVA following exposure to lethal doses of radiation (Menon, et.al., 2009). Following sub-
lethal and treatment doses of radiation, findings have demonstrated blood cell protection from DNA damage and lipid peroxidation, increased antioxidant activity, and increased aerobic metabolism following prophylactic and immediate administration of LAMC formulation (Ramachandran, et.al., 2010; Sudheesh, et.al., 2009, 2010). Furthermore, recent studies have exhibited enhanced DNA repair in rodents following LAMC administration (Menon and Nair, 2011). The suggested human dose to potentiate radiotherapy and reduce side-effects is 4 tsp./70 kg, while the prophylactic dose studied to protect DNA, increase cellular antioxidants, decrease lipid peroxidation, and facilitate DNA repair is 2 tsp./70 kg daily. Treatment-induced fatigue may be alleviated with as little as 0.5 tsp./70 kg daily.
POLY-MVA AND AUTOIMMUNE DISEASES
The usual medical treatments for autoimmune diseases, in which the immune system overreacts and creates inflammation somewhere in the body, include chemotherapy drugs and high doses of steroids. These therapies can be more devastating than the disease itself. It appears that POLY-MVA may offer a nontoxic alternative to those who suffer from autoimmune conditions.
Psoriasis is a skin condition that affects more than 7 million Americans. It is believed that it may be caused by an autoimmune process. It is characterized by itchy, flaky, reddened patches of skin that can be isolated to small areas or can affect almost the entire body. Practitioners who use POLY-MVA have found that both oral and topical versions are effective for the treatment of psoriasis - even in the most severe cases. Other autoimmune diseases, including multiple sclerosis and lupus, have also been successfully treated with POLY-MVA
Research is underway into the use of POLY-MVA for autoimmune diseases.
POLY-MVA AND ENDOMETRIOSIS
Endometriosis is a condition that afflicts 10-20% of all women in the United States. Women with endometriosis suffer from severe menstrual cramps (dysmenorrhea) with dull, aching pain in the pelvis, lower abdomen and back. Endometriosis develops when endometrial cells from the lining of the uterus migrate to locations outside the uterus and implant themselves on the ovaries, intestines and bladder. During the menses, and over time as the patient gets older, these misplaced cells grow, causing increasing pain.
There are no specific laboratory tests to diagnose endometriosis. The only way to diagnose endometriosis is to have a laparoscopy procedure in which the doctor looks into the abdomen using a fiberoptic instrument known as a laparoscope. The extent of the condition can be assessed and, if necessary, laser therapy can remove the large masses.
POLY-MVA offers a remarkably effective alternative treatment for endometriosis. By enhancing the function of the liver, POLY-MVA helps move blood out of the pelvis via the portal vein, and the endometriosis cells appear to implode and disappear. Although research is still needed to elucidate the exact mechanism of POLY-MVA in the treatment of endometriosis, it is clear that many women sufferings from this debilitating condition can be helped by treatment with POLY-MVA
POLY-MVA FOR PETS
The cancer epidemic has struck our animal companions, too. It appears that POLY-MVA can help and support them, as well. Veterinarians across the country are finding that POLY-
MVA has remarkable cancer-suppressive and, in many cases, cancer-reversing effects in animals. In 2005, a study of the effectiveness and safety of POLY-MVA for pets with cancer was completed by Gregory K. Ogilvie, DVM, a Veterinary Oncology specialist. To date, hundreds of animals have been using the POLY-MVA with amazing results. Hopes are that the study will be completed by the end of 2006 with data that will be publishable. Ask your veterinarian about POLY-MVA if you think your pet can benefit from it.
POLY-MVA AS PART OF A DAILY NUTRITIONAL REGIMEN
Those who use POLY-MVA as a nutritional supplement, or as a treatment, report that they feel more energetic almost immediately. This compound re-energizes cells, particularly those under stress. It is an ideal oral antioxidant that strengthens immune response and increases energy. POLY-MVA helps the body to perform at optimal levels by "supercharging" the cells and supplying nutrients that can easily be assimilated. As a preventive agent, it helps to avoid the age-related breakdown mainly associated with free radical damage to cellular structure and function, and in the process, it decreases vulnerability to disease.
DOSAGE RECOMMENDATIONS
If you wish to take POLY-MVA for health maintenance and prevention, take 1/4 to 2 teaspoon per day as part of your regular daily regimen. For best absorption, it should be taken 30 minutes prior to eating or taking other supplements.
If you are fighting early-stage disease, start with a loading dose of 8 teaspoons a day, divided into 2 teaspoons four times daily for at least two-three months. Then, reduce your dosage to 2 teaspoons twice daily (for a total of 4 teaspoons per day), gradually reducing further
to 1 to 2 teaspoons daily to maintain health. If your situation is more advanced, you may require a larger dose for a longer period. Enlist the guidance of your healthcare team to decide how long to take the higher dosage. Although some patients see quick changes in their medical condition, others need to take POLY-MVA for a minimum of two to six months before major changes are documented. If you do not notice an immediate difference, keep in mind that on average, four weeks pass before results are seen and felt. You may also consider consulting with your physician regarding the possibility of using intravenous POLY-MVA. Intravenous POLY-MVA given prior to oxidative therapies, such as ozone therapy and hydrogen peroxide therapy, is a very powerful jump-start to improved bioenergetic function.
When taking POLY-MVA for cancer, keep in mind that cancer cell "die-off" can cause temporary increases in cancer marker tests, such as the AMAS test, and that POLY-MVA may act as a paramagnetic contrast agent, which means that it can cause changes in MRI scans which can be mistaken for other growths.
For maximum benefit, POLY-MVA users can refer to the POLY-MVA website, or call the Foundation for the Advancement in Cancer Research Foundation at 866-5-CANCER, or visit
www.facr.org for further information (see the Resources section). You may be able to locate a practitioner in your area who can guide you in an alternative program that includes POLY-MVA; review the list of providers on the POLY-MVA website.
FURTHER RECOMMENDATIONS
Based on existing research, taking extremely high doses of other antioxidants is recommended around each other while taking POLY-MVA to better attain the therapeutic effects
of each therapy. If antioxidant therapy is deemed appropriate, POLY-MVA and the antioxidant(s) should be taken on an alternating schedule with several hours between therapies. For example, if you are taking vitamin C in doses of 50,000 to 75,000 milligrams per day, wait four hours after taking the vitamin C before taking POLY-MVA. There is evidence that supplemental Coenzyme Q10, (CoQ10) acts in a synergistic manner with POLY-MVA, and should be taken at the same time as this supports the electron transport chain function as well.. The use of nicotine products or steroid drugs may diminish the effectiveness of POLYMVA. Smoking is obviously not a good idea for people who are dealing with disease and highdose steroids are many times used in cancer therapy and an increased amount of LAMC will be needed to overcome those conditions Any changes in medication use should be under close physician supervision.
Conclusion
It’s the sincere hope that this book has introduced you to the origin and potential uses of the unique and remarkable compound POLY-MVA (LAMCs). As time goes on, new research will undoubtedly reveal how beneficial POLY-MVA can be - not only in the treatment of cancer but also for lyme, cardio vascular, ALS, dementia, endometriosis, MS, diabetic neuropathy, psoriasis and other metabolic/autoimmune disorders, for the prevention of brain damage caused by stroke, and for the promotion of optimal health, energy and longevity.
LAMC compounds were specifically designed to support healthy cells with the goal of selectively destroying abnormal cells without harming noncancerous cells. The manner in which POLY-MVA does so has yet to be completely explained across all the cases that have been seen,
but the research and the success stories from patients are exciting and compelling enough to continue the journey - and the substances safety is enough - to merit its use by anyone who wishes to maintain health and vitality and or reverse or prevent degenerative diseases.
Although a regimen of POLY-MVA can be more expensive than traditional supplements, the potential benefits far exceed the cost. Palladium at times has been more expensive than gold. At present, none of the POLY-MVA are covered by health insurance. But the evidence in its favor is strong, and it is the hope of everyone involved in offering this product that those who need it will find a way to get it for themselves or for their loved ones.
A supplement made by GM Laboratories is currently available from AMARC Enterprises and POLY-MVA (see Resources). More research is always needed and we look forward to helping create more healing.
METHODS AND MATERIALS:
The Lipoic Acid Mineral Complex (LAMC) referred in certain studies in this book was either DNA Reductase or Poly-MVA, manufactured by GM Labs and distributed by PolyMVA of San Diego, California: 619-401-0715 or www.polymva.com or polymva.store
LIPOIC ACID MINERAL COMPLEX, POLY-MVA and LAMC are registered trademarks.
For information about Lipoic Acid Mineral Complex or to find a physician who utilizes it, visit the Survivors website at www.polymvasurvivors.org and Cancer Foundation website at